bluzon的个人主页 - 老虎社区

bluzon

暂无个人介绍

IP属地：未知

40关注

0粉丝

0主题

0勋章

2021-06-29

[财迷] [财迷] [财迷]

抱歉，原内容已删除

2021-06-14

Ok

Is fuboTV at Risk From This World Cup Controversy?<blockquote>富波电视是否因这场世界杯争议而面临风险？</blockquote>

2021-08-09

[财迷] [财迷] [财迷]

抱歉，原内容已删除

2021-07-06

Yeah.........

抱歉，原内容已删除

2021-07-01

[得意] [得意] [得意] [得意] [得意] [鬼脸]

S&P 500 notches fifth straight record closing high, fifth straight quarterly gain<blockquote>标普500连续第五次创下收盘新高，连续第五个季度上涨</blockquote>

2021-06-28

Yes........

抱歉，原内容已删除

2021-07-05

[得意] [得意] [得意] [得意] [得意] [得意]

抱歉，原内容已删除

2021-06-28

👍👍👍👍👍👍

抱歉，原内容已删除

2021-06-16

Gd

抱歉，原内容已删除

2021-07-05

[得意] [得意] [得意] [得意] [鬼脸] [鬼脸] [鬼脸]

抱歉，原内容已删除

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3564622621302285","uuid":"3564622621302285","gmtCreate":1601530228734,"gmtModify":1601530228734,"name":"bluzon","pinyin":"bluzon","introduction":"","introductionEn":"","signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":40,"tweetSize":20,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-3","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"偶像虎友","description":"加入老虎社区1500天","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.11.10","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001}],"userBadgeCount":1,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":896701968,"gmtCreate":1628603814354,"gmtModify":1633745805226,"author":{"id":"3564622621302285","authorId":"3564622621302285","name":"bluzon","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564622621302285","authorIdStr":"3564622621302285"},"themes":[],"htmlText":"[呆住]&nbsp;[呆住]&nbsp;[呆住]&nbsp;","listText":"[呆住]&nbsp;[呆住]&nbsp;[呆住]&nbsp;","text":"[呆住] [呆住] [呆住]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/896701968","repostId":"1109397612","repostType":4,"repost":{"id":"1109397612","kind":"news","pubTimestamp":1628578754,"share":"https://www.laohu8.com/m/news/1109397612?lang=zh_CN&edition=full","pubTime":"2021-08-10 14:59","market":"us","language":"en","title":"Moderna Is A Winner In COVID-19 Vaccines, But What's Next?<blockquote>Moderna是新冠肺炎疫苗的赢家，但下一步是什么？</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1109397612","media":"seeking alpha","summary":"Investment Thesis\nModerna (MRNA) and Novavax (NVAX) released their respective Q2 earnings one after ","content":"<p>Investment Thesis</p><p><blockquote>投资论文</blockquote></p><p> Moderna (MRNA) and <a href=\"https://laohu8.com/S/NVAX\">Novavax</a> (NVAX) released their respective <a href=\"https://laohu8.com/S/QTWO\">Q2</a> earnings <a href=\"https://laohu8.com/S/AONE.U\">one</a> after the other, with Moderna indicating encouraging progress in its mRNA vaccine programs along with its COVID-19 vaccine production ramp. At the same time, Novavax surprised the market with its delay in filing for emergency use authorization ((EUA)) with the US government ((USG)).</p><p><blockquote>现代（MRNA）和<a href=\"https://laohu8.com/S/NVAX\">Novavax</a>(NVAX)发布了各自的<a href=\"https://laohu8.com/S/QTWO\">Q2</a>收入<a href=\"https://laohu8.com/S/AONE.U\">一</a>一个接一个，Moderna表示其mRNA疫苗项目以及COVID-19疫苗产量的增加取得了令人鼓舞的进展。与此同时，Novavax延迟向美国政府（（USG））提交紧急使用授权（（EUA））令市场感到意外。</blockquote></p><p> Moderna has continued to make excellent momentum as the company took full advantage of a highly successful COVID-19 vaccine program to develop the other vaccines in other therapeutic areas to future-proof its revenue sustainability, as the world gradually moves on to a world where COVID-19 is endemic.</p><p><blockquote>随着世界逐渐走向新冠肺炎流行的世界，Moderna充分利用非常成功的COVID-19疫苗计划在其他治疗领域开发其他疫苗，以确保其收入的可持续性，从而继续保持良好的势头。</blockquote></p><p> This article provides a timely update for our readers to decide whether Moderna is still a good investment given the recent run-up that we think has resulted in a high amount of optimism being baked into its price.</p><p><blockquote>本文为我们的读者提供了及时的更新，以决定Moderna是否仍然是一项不错的投资，因为我们认为最近的上涨导致了对其价格的高度乐观。</blockquote></p><p> Q2 Earnings Recap</p><p><blockquote>第二季度收益回顾</blockquote></p><p> <i>Moderna quarterly revenue surprise. Source: Seeking Alpha Premium</i></p><p><blockquote><i>Moderna季度收入惊喜。资料来源：寻求Alpha Premium</i></blockquote></p><p> <i>Moderna quarterly EPS surprise. Source: Seeking Alpha Premium</i></p><p><blockquote><i>Moderna季度每股收益惊喜。资料来源：寻求Alpha Premium</i></blockquote></p><p> Moderna reported a solid Q2 report card, keeping in line with the momentum from Q1, as the company posted revenue of $4.354B and EPS of $6.46, which were 10.3% and 2.8% above the consensus estimates.</p><p><blockquote>Moderna公布了稳健的第二季度成绩单，与第一季度的势头保持一致，该公司公布的收入为$4.354 B，每股收益为$6.46，分别比市场普遍预期高出10.3%和2.8%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/727827b49e82cf15b729bc1d2efd38fa\" tg-width=\"600\" tg-height=\"371\" referrerpolicy=\"no-referrer\"><i>Moderna H1'21 revenue and FY21 consensus estimate. Data source: S&amp;P Capital IQ</i></p><p><blockquote><i>Moderna H1'21收入和21财年共识预期。数据来源：标普资本智商</i></blockquote></p><p> Importantly, Moderna posted a highly impressive QoQ increase of 125% in revenue from $1.94B in Q1'21 to $4.35B in Q2'21. However, Moderna would need to significantly ramp up in H2'21 for the company to meet the Street's FY21 estimates as H1'21's revenue of $6.29B accounted for only 31.2% of the FY21 consensus estimates.</p><p><blockquote>重要的是，Moderna的收入环比增长了125%，从21年第一季度的$1.94 B增至21年第二季度的$4.35 B。然而，Moderna需要在21年上半年大幅增长才能满足华尔街对21财年的预期，因为21年上半年的收入为$6.29 B，仅占21财年普遍预期的31.2%。</blockquote></p><p> To that, Moderna has assured investors that based on the company's signed advanced purchase agreements ((APA)) for FY21, Moderna indicated that \"expected delivery in 2021reflect the current full-year total of approximately $20 billion in anticipated product sales.\" The company continues to anticipate a supply of at least 800M to 1B doses for 2021.</p><p><blockquote>对此，Moderna向投资者保证，根据该公司签署的2021财年提前购买协议((APA))，Moderna表示“预计2021年交付反映了当前全年预期产品销售额约200亿美元。”该公司继续预计2021年的供应量至少为8亿至10亿剂。</blockquote></p><p> Studying Moderna's Gross Margins and Pricing Strategy</p><p><blockquote>研究Moderna的毛利率和定价策略</blockquote></p><p> <i>Moderna quarterly gross margin. Data source: S&amp;P Capital IQ</i></p><p><blockquote><i>Moderna季度毛利率。数据来源：标普资本智商</i></blockquote></p><p> The production ramp in Q2'21 has also improved Moderna's economies of scale as its gross margin improved markedly in Q2'21, as Moderna's total cost of revenue represents about 26.9% of Q2'21 revenue.</p><p><blockquote>21年第二季度的产量增长也提高了Moderna的规模经济，其毛利率在21年第二季度显着提高，因为Moderna的总收入成本约占21年第二季度收入的26.9%。</blockquote></p><p> Crucially, Moderna has indicated that its COVID-19H1'21's product salesof $5.93B which constitute about 94.3% of H1'21's total revenue, has a much lower cost of revenue. Based on our findings, Moderna's COVID-19 product sales have a cost of revenue of $1.1B, representing about 18.5% of H1'21's COVID-19 product revenue, therefore indicating that the average gross margin for its COVID-19 product is about 81.5%. The company has also emphasized that it \"expects the average cost total of sales as a percent of product sales to be between 18% and 20% compared to our previous outlook of approximately 20% of product sales. This reflects the successful ramp-up of this global manufacturing network.\"</p><p><blockquote>至关重要的是，Moderna表示，其COVID-19H1'21的产品销售额为$59.3亿，约占H1'21总收入的94.3%，其收入成本要低得多。根据我们的调查结果，Moderna的COVID-19产品销售收入成本为$1.1 B，约占H1'21 COVID-19产品收入的18.5%，因此表明其COVID-19产品的平均毛利率约为81.5%%。该公司还强调，“预计平均总销售成本占产品销售额的百分比将在18%至20%之间，而我们之前预计约占产品销售额的20%。这反映了成功的增长”这个全球制造网络。”</blockquote></p><p> Since Moderna delivered 199M doses in Q2'21 and 102M doses in Q1'21, the company delivered a collective amount of 301M doses in H1'21 that was recognized as product revenue. Given that our cost of revenue is about $1.1B for H1'21, we could thus derive an average cost per dose of about $3.65, which the company has highlighted that it expects to maintain for the rest of 2021.</p><p><blockquote>由于Moderna在21年第二季度交付了1.99亿剂疫苗，在21年第一季度交付了1.02亿剂疫苗，因此该公司在21年上半年总共交付了3.01亿剂疫苗，并被确认为产品收入。鉴于我们21年上半年的收入成本约为$1.1 B，因此我们可以得出每剂的平均成本约为$3.65，该公司强调预计将在2021年剩余时间内维持这一成本。</blockquote></p><p> Before we carry on, Moderna has highlighted that the cost of sales that the company reflected in H1'21 of $943M included their \"zero-cost COVID-19 inventory,\" as the company emphasized: \"At the end of the first quarter of 2021, we had substantially utilized our zero-cost COVID-19 vaccine inventory. Therefore, if inventory sold for the six months ended June 30, 2021, were valued at cost, our cost of sales for the period would have been $1.1 billion.\" Therefore, based on our computation above, we believe it's important to reflect the cost of sales more accurately, which the company also corroborates in their earnings call.</p><p><blockquote>在我们继续之前，Moderna强调，该公司在H1'21中反映的9.43亿美元的销售成本包括其“零成本COVID-19库存”，正如该公司强调的那样：“截至2021年第一季度末，我们已充分利用了零成本COVID-19疫苗库存。因此，如果截至2021年6月30日的六个月销售的库存按成本估值，我们该期间的销售成本将为11亿美元。”因此，根据我们上面的计算，我们认为更准确地反映销售成本非常重要，该公司也在其收益看涨期权中证实了这一点。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/28b81eba2e15387ebf431cce2b895aba\" tg-width=\"600\" tg-height=\"371\" referrerpolicy=\"no-referrer\">Moderna Spikevax pricing tiers. Data source: Moderna</p><p><blockquote>Moderna Spikevax定价等级。数据来源：Moderna</blockquote></p><p> Moderna adopts a tiered pricing model to distribute its vaccines equitably. For the USG, the company has applied a \"favorable\" pricing model because of the US government's funding as well as the 500M doses order that the USG committed to Moderna, which the company emphasized, \"is very large.\"</p><p><blockquote>Moderna采用分级定价模式来公平分配其疫苗。对于美国政府来说，由于美国政府的资助以及美国政府向Moderna承诺的5亿剂订单，该公司采用了“有利”的定价模式，该公司强调该订单“非常大”。</blockquote></p><p></p><p> The other higher-income countries paid between $32 and $37, including larger orders from countries that include the EU with an APA of260M dosesfor 2021. Thus, applying Moderna's large contract discount logic, we should expect the average EU pricing to be at the lower end of the $32 to $37 range.</p><p><blockquote>其他高收入国家支付了32至37美元，其中包括来自欧盟等国家的更大订单，2021年APA为2.6亿剂。因此，应用Moderna的大合同折扣逻辑，我们应该预计欧盟平均定价将处于32美元至37美元范围的下限。</blockquote></p><p> For the lower to middle-income countries, even though the company did not explicitly disclose the exact price range, the company highlighted that this category \"received the lowest-tiered pricing, including those sales to COVAX, which are considerably lower than the price to the U.S. government.\"</p><p><blockquote>对于中低收入国家，尽管该公司没有明确披露确切的价格范围，但该公司强调，该类别“获得了最低等级的定价，包括向COVAX销售的产品，其价格远低于向美国政府。”</blockquote></p><p> For Moderna, we could easily derive its average price at about $19.7 ($5.93B/301M) per dose for H1'21, even though the company has emphasized that it's likely to be reduced moving into 2022 as they ramp the production for delivery to COVAX as well as the lower and middle-income countries, especially since the COVAX APA is set to increase from 34M doses in 2021 to 117M doses in 2022, with an option to increase up to 350M doses.</p><p><blockquote>对于Moderna来说，我们可以很容易地得出其H1'21的平均价格约为每剂19.7美元（59.3亿美元/3.01亿美元），尽管该公司强调，随着他们提高产量以交付给COVAX以及中低收入国家，特别是因为COVAX APA将从2021年的3400万剂增加到2022年的1.17亿剂，并可选择增加到3.5亿剂。</blockquote></p><p> COVAX reported an average price of about$5.20 per dose; thus, it would be useful for investors to continue monitoring the impact on the average price for mRNA-1273 moving forward. Moderna has also indicated that it is expecting more price competition as we move from a pandemic towards a world where COVID-19 is endemic. In addition, it may also be useful to watch closely for further improvement in its economies of scale as the company ramps production from an estimated 800M to 1B doses in 2021 to 2B to 3B doses in 2022.</p><p><blockquote>COVAX报告的平均价格约为每剂5.20美元；因此，投资者继续监测对mRNA-1273未来平均价格的影响将是有用的。Moderna还表示，随着我们从大流行转向新冠肺炎流行的世界，它预计会出现更多的价格竞争。此外，随着该公司将产量从2021年估计的8亿至10亿剂提高到2022年的20亿至30亿剂，密切关注其规模经济的进一步改善也可能是有用的。</blockquote></p><p> Moderna's Strategy Moving <a href=\"https://laohu8.com/S/FORD\">Forward</a></p><p><blockquote>Moderna的战略正在转变<a href=\"https://laohu8.com/S/FORD\">向前</a></blockquote></p><p> Share of the population fully vaccinated against COVID-19. Source: OWID</p><p><blockquote>完全接种新冠肺炎疫苗的人口比例。资料来源：OWID</blockquote></p><p> It's straightforward that Moderna has ramped production significantly to compete for the next phase in COVID-19 distribution for its mRNA-1273 product for countries within the COVAX category in 2022 and 2023 as the high-income countries are starting to approach the 60% to 70% fully vaccinated mark. However, we could clearly glean from the chart above where only 15% of the total world population has been fully vaccinated, while countries like Indonesia and India have only 8% and 7.8% of their population fully inoculated, and South America's 20.9% still has a long way to go as well.</p><p><blockquote>显而易见，随着高收入国家开始接近60%至70%，Moderna已大幅提高产量，以竞争2022年和2023年其mRNA-1273产品在COVAX类别国家的下一阶段COVID-19分销。完全接种疫苗的标记。然而，我们可以从上面的图表中清楚地收集到，世界总人口中只有15%的人完全接种了疫苗，而印度尼西亚和印度等国家只有8%和7.8%的人口完全接种了疫苗，南美洲的20.9%也还有很长的路要走。</blockquote></p><p> Moving forward, the strategy for the high-income countries is starting to move towards booster shots. We think this is where Moderna, as one of the 2 mRNA vaccines makers, has sufficiently proven its worth against <a href=\"https://laohu8.com/S/PFE\">Pfizer</a>-BioNTech as the company's recent COVE study demonstrated that mRNA-1273 could maintain the efficacy of 93.2%, 4 to 6 months after the second dose, and a 98.2% efficacy against severe disease, as well as a 100% efficacy against death caused by COVID-19. As compared to Pfizer-BioNTech's vaccine, where the efficacy is expected to drop to84%after 6 months, we would clearly applaud the breathtaking results that clearly demonstrate the superiority of Moderna's Spikevax against Comirnaty.</p><p><blockquote>展望未来，高收入国家的战略开始转向加强注射。我们认为，Moderna作为两家mRNA疫苗制造商之一，已经充分证明了其对抗的价值<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>-BioNTech as公司最近的COVE研究表明，mRNA-1273在第二剂后4至6个月可保持93.2%的疗效，对重症的疗效为98.2%，对新冠肺炎引起的死亡疗效为100%。与辉瑞-BioNTech的疫苗相比，预计6个月后疗效将降至84%，我们显然会对令人惊叹的结果表示赞赏，这些结果清楚地证明了Moderna的Spikevax相对于Comirnaty的优越性。</blockquote></p><p> To this Moderna Co-founder and Chairman Dr. Noubar Afeyan clearly articulated who he thinks owns the superior mRNA technology for COVID-19 vaccine in the market (shout-out to Pfizer-BioNTech folks):</p><p><blockquote>Moderna联合创始人兼董事长Noubar Afeyan博士明确阐述了他认为谁拥有市场上用于COVID-19疫苗的卓越mRNA技术（向辉瑞-BioNTech人员大喊）：</blockquote></p><p>   We set outto develop the most effective vaccine against this virus that would last for the longest possible time, [helping] the largest number of people to be safe...And this is the first time we had data that at least showed that six months after the initial vaccinations were seeing essentially the same level of protection, which is very encouraging.  Moderna also emphasized that we should never underestimate the efficacy differences as just plain numbers, which in Moderna's and Pfizer-BioNTech's case amounted to 9.2% points. The company emphasized that:</p><p><blockquote>我们着手开发针对这种病毒的最有效的疫苗，这种疫苗将持续尽可能长的时间，[帮助]最多的人获得安全...这是我们第一次有数据至少显示，在初次接种疫苗六个月后，保护水平基本相同，这非常令人鼓舞。Moderna还强调，我们永远不应该将疗效差异低估为简单的数字，在Moderna和辉瑞-BioNTech的案例中，疗效差异达9.2%。公司强调：</blockquote></p><p></p><p>   The relative strength of the different vaccines suggested that small differences in efficacy would start to emerge to be larger differences in efficacy at about 200, 250 days as neutralizing antibody titers waned. And that may be what we're starting to see. And if you play that forward, if you assume [Professor Davenport of the University of <a href=\"https://laohu8.com/S/NGD\">New</a> South Wales, Australia] been right about those predictions, then that picture continues and continues through a year with continued declining neutralizing antibody titers over that time. And eventually, we therefore believe, a real increase in breakthrough infections and disease even with vaccinated participants, even with mRNA-1273.  Moderna has also presented clear findings where it expects that a booster shot would significantly increase the neutralizing titers. In contrast, without the booster, for test subjects 6 to 8 months after their second dose, the neutralizing titers have dropped so significantly that for the Beta, Gamma and Delta variants, the \"neutralizing titers had fallen below the detectable -- the level of detection of the assay for a decent number of participants in all 4 -- all 3 cases.\"</p><p><blockquote>不同疫苗的相对强度表明，随着中和抗体滴度减弱，效力的小差异将在约200、250天时开始表现为效力的大差异。这可能是我们开始看到的。如果你扮演那个前锋，如果你假设[达文波特教授<a href=\"https://laohu8.com/S/NGD\">新的</a>澳大利亚南威尔士]的这些预测是正确的，然后这种情况会持续一年，在此期间中和抗体滴度持续下降。因此，我们相信，最终，即使是接种疫苗的参与者，即使是mRNA-1273，突破性感染和疾病也会真正增加。Moderna还提出了明确的发现，预计加强注射将显着增加中和滴度。相比之下，在没有加强剂的情况下，对于第二次给药后6至8个月的测试受试者，中和滴度显著下降，以至于对于β、γ和δ变体，“中和滴度已降至可检测水平以下——在所有4-所有3种情况下，相当数量的参与者的检测水平。”</blockquote></p><p> As a result, we expect Moderna has strongly assembled the case for a booster with strong evidence suggesting their importance to protect against the new potential variants that may emerge, which Moderna has certainly warned: \"...It seems logical to us that those 3 mutations present in the Beta, Gamma line and those 2 mutations present in the Delta might find some way to combine in new and potentially scary ways. And if that came with the increased transmissibility, [the] force of infection that Delta can achieve, that might be a significant threat. And so we view our multivalent platform as the best place for us to try and anticipate that threat.\"</p><p><blockquote>因此，我们预计Moderna已经强有力地组装了加强剂的案例，有强有力的证据表明它们对于防止可能出现的新的潜在变异的重要性，Moderna当然警告过：“...对我们来说，β、γ线中存在的3种突变和δ中存在的2种突变可能会找到某种方式以新的和潜在的可怕方式结合起来，这似乎是合乎逻辑的。如果这伴随着传播性的增加，德尔塔可以达到的感染强度，这可能是一个重大威胁。因此，我们认为我们的多价平台是我们尝试和预测这种威胁的最佳场所。”</blockquote></p><p> The company is developing a \"proactive\" multivalent platform where it combines \"different variants into a single vaccine\" as its strategy to combat potential variants that are expected to emerge. Based on the company's assays study, this platform clearly outperformed the other candidates in its study. In addition, it stood out as a strong candidate to be used as a booster option, even though the primary mRNA-1273 candidate can also be used effectively as a booster.</p><p><blockquote>该公司正在开发一种“主动”的多价平台，将“不同的变种组合成一种疫苗”，作为对抗预计出现的潜在变种的策略。根据该公司的检测研究，该平台在其研究中明显优于其他候选平台。此外，尽管初级mRNA-1273候选物也可以有效地用作加强剂，但它作为用作加强剂选项的有力候选物脱颖而出。</blockquote></p><p> However, in a fast-evolving situation with COVID-19, we think having more efficacious options are only going to be beneficial as vaccine makers try to anticipate and are proactive against potential new and more potent antigens where Moderna even admitted that the Delta variant had humbled them, as it added: \"I think the Delta variant has taught us to also be incredibly humble in the face of the virus' ability to fight back and increase its transmission. I mean, I think most of us would have thought SARS-CoV-2 was a pretty good infector earlier this year. Delta has shown us that it can make huge steps forward.\"</p><p><blockquote>然而，在COVID-19快速发展的情况下，我们认为拥有更有效的选择只会是有益的，因为疫苗制造商试图预测并积极对抗潜在的新的、更有效的抗原，Moderna甚至承认德尔塔变异毒株已经谦卑了他们，并补充道：“我认为德尔塔变异毒株教会了我们，面对病毒反击和增加传播的能力，也要非常谦卑。我的意思是，我认为我们大多数人今年早些时候都会认为新型冠状病毒是一个相当不错的感染者。达美航空向我们展示了它可以取得巨大的进步。”</blockquote></p><p> Risks to our Thesis</p><p><blockquote>我们论文的风险</blockquote></p><p> By now, it should be clear that 2022 is promising to be a year where Moderna would almost double or triple its supply to 2B or 3B doses, depending on whether the company is using 100 micrograms or 50 micrograms in its product moving forward. Pfizer-BioNTech is also expected to increase its capacity to 3B doses in 2022, while we also need to take into account Novavax's impending entry into the COVID-19 vaccines production game, as well as the Chinese vaccine makers who already have an annual capacity of 5B doses.</p><p><blockquote>到目前为止，应该很明显，2022年Moderna有望将其2B或3B剂量的供应量增加近一倍或三倍，这取决于该公司未来在其产品中使用100微克还是50微克。辉瑞-BioNTech预计也将在2022年将其产能提高到3B剂，同时我们还需要考虑到Novavax即将进入COVID-19疫苗生产游戏，以及已经拥有5B剂年产能的中国疫苗制造商。</blockquote></p><p> We think there is a realistic chance where Moderna may be facing an over-supply situation even though it may have proven itself to be the superior mRNA vaccine for now against Pfizer-BioNTech.</p><p><blockquote>我们认为Moderna很可能面临供应过剩的情况，尽管它可能已经证明自己是目前对抗辉瑞BioNTech的优质mRNA疫苗。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/3b54cee9edb8e398275290f3edcdb770\" tg-width=\"640\" tg-height=\"353\" referrerpolicy=\"no-referrer\">Revenue forecast mean consensus. Data source: S&amp;P Capital IQ</p><p><blockquote>收入预测意味着共识。数据来源：标普资本智商</blockquote></p><p> Therefore, we think the Street has prudently lowered its revenue estimates for Moderna over the next few years. The company is also likely to come under pricing pressure against the huge supply expected to come online.</p><p><blockquote>因此，我们认为华尔街谨慎地下调了Moderna未来几年的收入预期。由于预计将上线的大量供应，该公司也可能面临定价压力。</blockquote></p><p> However, we think Moderna is keenly aware of it. The company clearly highlighted that they had made good progress in the other 5 therapeutic areas that the company is involved in. Of notable mention is the fast track designation the company recently received from the US FDA for the company'sRSV vaccine candidate, mRNA-1345, especially when there is no approved RSV vaccine yet in the market.</p><p><blockquote>然而，我们认为Moderna敏锐地意识到了这一点。该公司明确强调，他们在该公司参与的其他5个治疗领域取得了良好进展。值得注意的是，该公司最近获得了美国FDA对该公司的RSV候选疫苗mRNA-1345的快速通道指定，特别是在市场上尚未批准的RSV疫苗的情况下。</blockquote></p><p> In addition, the company has also commenced on the Phase I/II study of its mRNA-1010 quadrivalent seasonal flu vaccine to target the seasonal flu market, where it's worth about $5B to $6B annually, according to Moderna's estimates, especially when the current flu vaccine efficacy is between 40% and 60% according toCDC data. Moderna expects its quadrivalent vaccine to be launched as early as 2023.</p><p><blockquote>此外，该公司还开始了其mRNA-1010四价季节性流感疫苗的I/II期研究，以瞄准季节性流感市场，根据Moderna的估计，季节性流感市场每年的价值约为50亿至60亿美元，特别是在目前的情况下根据CDC的数据，流感疫苗的效力在40%至60%之间。Moderna预计其四价疫苗最早将于2023年上市。</blockquote></p><p></p><p> Moderna is also expecting good results from its CMV vaccine, which is expected to be entering Phase III trials soon. It would also allow the company to tap into a market worth between $2B and $5B annually.</p><p><blockquote>Moderna还期待其CMV疫苗取得良好效果，预计很快将进入III期试验。这也将使该公司能够进入每年价值20亿美元至50亿美元的市场。</blockquote></p><p> Hence, we think that the company has been proactively working on the success of its mRNA-1273 to progress confidently along the other programs to sustain its commercial success beyond just being a COVID-19 vaccine maker. Therefore, we encourage investors to monitor its most advanced programs closely and keep pace with them moving forward.</p><p><blockquote>因此，我们认为该公司一直在积极致力于mRNA-1273的成功，以自信地推进其他项目，以维持其商业成功，而不仅仅是成为COVID-19疫苗制造商。因此，我们鼓励投资者密切关注其最先进的计划，并与他们保持同步。</blockquote></p><p> Valuations</p><p><blockquote>估值</blockquote></p><p> <img src=\"https://static.tigerbbs.com/69cb54a8282012f6cff4095f28e2a08f\" tg-width=\"640\" tg-height=\"176\" referrerpolicy=\"no-referrer\">Biotech peers valuation comp set. Source: TIKR</p><p><blockquote>生物技术同行估值比较集。来源：TIKR</blockquote></p><p> EV / Fwd Rev trend. Data source: S&amp;P Capital IQ</p><p><blockquote>EV/Fwd转速趋势。数据来源：标普资本智商</blockquote></p><p> Moderna is currently trading at an EV / Fwd Rev of about 8x, which interestingly comes in below its peers' mean multiple of 14.14x, where Moderna may look to be attractively valued. However, this assumes that Moderna can keep increasing its revenue strongly over the next few years, a point that we have raised previously may face significant headwinds ahead.</p><p><blockquote>Moderna目前的EV/Fwd Rev约为8倍，有趣的是，这低于同行14.14倍的平均倍数，而Moderna的估值可能看起来很有吸引力。然而，这是假设Moderna能够在未来几年内继续强劲增长其收入，我们之前提出的这一点可能会面临重大阻力。</blockquote></p><p> Importantly, we could see that based on the company's expected revenue moving forward, the company is not likely to see meaningful progress on its capital appreciation potential moving forward as its revenue multiple by the end of FY25 is expected to be about 14.6x, which is in line with the peers' mean multiple right now.</p><p><blockquote>重要的是，我们可以看到，根据该公司未来的预期收入，该公司未来的资本增值潜力不太可能取得有意义的进展，因为到2025财年末其收入倍数预计约为14.6倍，这与目前同行的平均倍数一致。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/a4cc567a1361ba17617927c47a803418\" tg-width=\"640\" tg-height=\"476\" referrerpolicy=\"no-referrer\">Street's mean price target. Source: TIKR</p><p><blockquote>Street的平均目标价。来源：TIKR</blockquote></p><p> Moreover, the Street is also not optimistic on MRNA making meaningful headway from here, and in fact, values the stock at about a 5.2x implied EV / Fwd Rev multiple, at a 35% discount from the last closing price. Analysts from <a href=\"https://laohu8.com/S/OPY\">Oppenheimer</a> also emphasized that \"MRNA sharesare fairly pricing a tremendous amount of future recurring revenues and pipeline progress...[arguing] that the company’s non-COVID pipeline remains 2-3 years away from reaching commercial success.\"</p><p><blockquote>此外，华尔街也不看好MRNA从这里取得有意义的进展，事实上，该股的估值约为隐含EV/Fwd Rev倍数的5.2倍，较上一收盘价折价35%。分析师来自<a href=\"https://laohu8.com/S/OPY\">奥本海默</a>还强调，“MRNA股票公平地定价了大量未来经常性收入和管道进展……[认为]该公司的非新冠管道距离取得商业成功还有2-3年的时间。”</blockquote></p><p> Our opinion is in line with the Street, and we think that a lot of optimism is currently being priced into Moderna at the moment. So we think if investors are sitting on decent profits right now, we strongly encourage you to at least take partial profits and take some risk off the table.</p><p><blockquote>我们的观点与华尔街的观点一致，我们认为Moderna目前的定价中包含了很多乐观情绪。因此，我们认为，如果投资者现在坐拥可观的利润，我们强烈建议您至少获利了结部分利润并消除一些风险。</blockquote></p><p> Price Action and Trend Analysis<img src=\"https://static.tigerbbs.com/766a37b6357b74ea899bd0e823ff64a2\" tg-width=\"640\" tg-height=\"391\" referrerpolicy=\"no-referrer\">Source: TradingView</p><p><blockquote>价格行为和趋势分析资料来源：TradingView</blockquote></p><p> While we are clear about MRNA's long-term uptrend bias (which is why we don't recommend a short-sell strategy against stocks with clear uptrend bias), we also think the stock's price action has recently shown signs of a climax top pattern.</p><p><blockquote>虽然我们清楚MRNA的长期上升趋势偏差（这就是为什么我们不建议对具有明显上升趋势偏差的股票采取卖空策略），但我们也认为该股的价格走势最近显示出高潮顶部模式的迹象。</blockquote></p><p> However, it's impossible to speculate exactly where the top is. Therefore, we think it's prudent for investors to take some profits off the table and wait for the euphoria to chill and cool down before considering adding exposure to MRNA again.</p><p><blockquote>然而，无法准确推测顶部在哪里。因此，我们认为投资者谨慎的做法是将部分利润撤出桌面，等待兴奋情绪降温后再考虑再次增加对MRNA的投资。</blockquote></p><p> We have already taken the opportunity of the stock's recent strength to lock in 50% of our profit on MRNA, with a view of locking in even more if we continue to see price action that shows a higher climax top tendency moving forward.</p><p><blockquote>我们已经利用该股近期走强的机会锁定了MRNA利润的50%，如果我们继续看到价格走势显示出更高的高潮顶部趋势，我们将锁定更多利润。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Is A Winner In COVID-19 Vaccines, But What's Next?<blockquote>Moderna是新冠肺炎疫苗的赢家，但下一步是什么？</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Is A Winner In COVID-19 Vaccines, But What's Next?<blockquote>Moderna是新冠肺炎疫苗的赢家，但下一步是什么？</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">seeking alpha</strong><span class=\"h-time small\">2021-08-10 14:59</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Investment Thesis</p><p><blockquote>投资论文</blockquote></p><p> Moderna (MRNA) and <a href=\"https://laohu8.com/S/NVAX\">Novavax</a> (NVAX) released their respective <a href=\"https://laohu8.com/S/QTWO\">Q2</a> earnings <a href=\"https://laohu8.com/S/AONE.U\">one</a> after the other, with Moderna indicating encouraging progress in its mRNA vaccine programs along with its COVID-19 vaccine production ramp. At the same time, Novavax surprised the market with its delay in filing for emergency use authorization ((EUA)) with the US government ((USG)).</p><p><blockquote>现代（MRNA）和<a href=\"https://laohu8.com/S/NVAX\">Novavax</a>(NVAX)发布了各自的<a href=\"https://laohu8.com/S/QTWO\">Q2</a>收入<a href=\"https://laohu8.com/S/AONE.U\">一</a>一个接一个，Moderna表示其mRNA疫苗项目以及COVID-19疫苗产量的增加取得了令人鼓舞的进展。与此同时，Novavax延迟向美国政府（（USG））提交紧急使用授权（（EUA））令市场感到意外。</blockquote></p><p> Moderna has continued to make excellent momentum as the company took full advantage of a highly successful COVID-19 vaccine program to develop the other vaccines in other therapeutic areas to future-proof its revenue sustainability, as the world gradually moves on to a world where COVID-19 is endemic.</p><p><blockquote>随着世界逐渐走向新冠肺炎流行的世界，Moderna充分利用非常成功的COVID-19疫苗计划在其他治疗领域开发其他疫苗，以确保其收入的可持续性，从而继续保持良好的势头。</blockquote></p><p> This article provides a timely update for our readers to decide whether Moderna is still a good investment given the recent run-up that we think has resulted in a high amount of optimism being baked into its price.</p><p><blockquote>本文为我们的读者提供了及时的更新，以决定Moderna是否仍然是一项不错的投资，因为我们认为最近的上涨导致了对其价格的高度乐观。</blockquote></p><p> Q2 Earnings Recap</p><p><blockquote>第二季度收益回顾</blockquote></p><p> <i>Moderna quarterly revenue surprise. Source: Seeking Alpha Premium</i></p><p><blockquote><i>Moderna季度收入惊喜。资料来源：寻求Alpha Premium</i></blockquote></p><p> <i>Moderna quarterly EPS surprise. Source: Seeking Alpha Premium</i></p><p><blockquote><i>Moderna季度每股收益惊喜。资料来源：寻求Alpha Premium</i></blockquote></p><p> Moderna reported a solid Q2 report card, keeping in line with the momentum from Q1, as the company posted revenue of $4.354B and EPS of $6.46, which were 10.3% and 2.8% above the consensus estimates.</p><p><blockquote>Moderna公布了稳健的第二季度成绩单，与第一季度的势头保持一致，该公司公布的收入为$4.354 B，每股收益为$6.46，分别比市场普遍预期高出10.3%和2.8%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/727827b49e82cf15b729bc1d2efd38fa\" tg-width=\"600\" tg-height=\"371\" referrerpolicy=\"no-referrer\"><i>Moderna H1'21 revenue and FY21 consensus estimate. Data source: S&amp;P Capital IQ</i></p><p><blockquote><i>Moderna H1'21收入和21财年共识预期。数据来源：标普资本智商</i></blockquote></p><p> Importantly, Moderna posted a highly impressive QoQ increase of 125% in revenue from $1.94B in Q1'21 to $4.35B in Q2'21. However, Moderna would need to significantly ramp up in H2'21 for the company to meet the Street's FY21 estimates as H1'21's revenue of $6.29B accounted for only 31.2% of the FY21 consensus estimates.</p><p><blockquote>重要的是，Moderna的收入环比增长了125%，从21年第一季度的$1.94 B增至21年第二季度的$4.35 B。然而，Moderna需要在21年上半年大幅增长才能满足华尔街对21财年的预期，因为21年上半年的收入为$6.29 B，仅占21财年普遍预期的31.2%。</blockquote></p><p> To that, Moderna has assured investors that based on the company's signed advanced purchase agreements ((APA)) for FY21, Moderna indicated that \"expected delivery in 2021reflect the current full-year total of approximately $20 billion in anticipated product sales.\" The company continues to anticipate a supply of at least 800M to 1B doses for 2021.</p><p><blockquote>对此，Moderna向投资者保证，根据该公司签署的2021财年提前购买协议((APA))，Moderna表示“预计2021年交付反映了当前全年预期产品销售额约200亿美元。”该公司继续预计2021年的供应量至少为8亿至10亿剂。</blockquote></p><p> Studying Moderna's Gross Margins and Pricing Strategy</p><p><blockquote>研究Moderna的毛利率和定价策略</blockquote></p><p> <i>Moderna quarterly gross margin. Data source: S&amp;P Capital IQ</i></p><p><blockquote><i>Moderna季度毛利率。数据来源：标普资本智商</i></blockquote></p><p> The production ramp in Q2'21 has also improved Moderna's economies of scale as its gross margin improved markedly in Q2'21, as Moderna's total cost of revenue represents about 26.9% of Q2'21 revenue.</p><p><blockquote>21年第二季度的产量增长也提高了Moderna的规模经济，其毛利率在21年第二季度显着提高，因为Moderna的总收入成本约占21年第二季度收入的26.9%。</blockquote></p><p> Crucially, Moderna has indicated that its COVID-19H1'21's product salesof $5.93B which constitute about 94.3% of H1'21's total revenue, has a much lower cost of revenue. Based on our findings, Moderna's COVID-19 product sales have a cost of revenue of $1.1B, representing about 18.5% of H1'21's COVID-19 product revenue, therefore indicating that the average gross margin for its COVID-19 product is about 81.5%. The company has also emphasized that it \"expects the average cost total of sales as a percent of product sales to be between 18% and 20% compared to our previous outlook of approximately 20% of product sales. This reflects the successful ramp-up of this global manufacturing network.\"</p><p><blockquote>至关重要的是，Moderna表示，其COVID-19H1'21的产品销售额为$59.3亿，约占H1'21总收入的94.3%，其收入成本要低得多。根据我们的调查结果，Moderna的COVID-19产品销售收入成本为$1.1 B，约占H1'21 COVID-19产品收入的18.5%，因此表明其COVID-19产品的平均毛利率约为81.5%%。该公司还强调，“预计平均总销售成本占产品销售额的百分比将在18%至20%之间，而我们之前预计约占产品销售额的20%。这反映了成功的增长”这个全球制造网络。”</blockquote></p><p> Since Moderna delivered 199M doses in Q2'21 and 102M doses in Q1'21, the company delivered a collective amount of 301M doses in H1'21 that was recognized as product revenue. Given that our cost of revenue is about $1.1B for H1'21, we could thus derive an average cost per dose of about $3.65, which the company has highlighted that it expects to maintain for the rest of 2021.</p><p><blockquote>由于Moderna在21年第二季度交付了1.99亿剂疫苗，在21年第一季度交付了1.02亿剂疫苗，因此该公司在21年上半年总共交付了3.01亿剂疫苗，并被确认为产品收入。鉴于我们21年上半年的收入成本约为$1.1 B，因此我们可以得出每剂的平均成本约为$3.65，该公司强调预计将在2021年剩余时间内维持这一成本。</blockquote></p><p> Before we carry on, Moderna has highlighted that the cost of sales that the company reflected in H1'21 of $943M included their \"zero-cost COVID-19 inventory,\" as the company emphasized: \"At the end of the first quarter of 2021, we had substantially utilized our zero-cost COVID-19 vaccine inventory. Therefore, if inventory sold for the six months ended June 30, 2021, were valued at cost, our cost of sales for the period would have been $1.1 billion.\" Therefore, based on our computation above, we believe it's important to reflect the cost of sales more accurately, which the company also corroborates in their earnings call.</p><p><blockquote>在我们继续之前，Moderna强调，该公司在H1'21中反映的9.43亿美元的销售成本包括其“零成本COVID-19库存”，正如该公司强调的那样：“截至2021年第一季度末，我们已充分利用了零成本COVID-19疫苗库存。因此，如果截至2021年6月30日的六个月销售的库存按成本估值，我们该期间的销售成本将为11亿美元。”因此，根据我们上面的计算，我们认为更准确地反映销售成本非常重要，该公司也在其收益看涨期权中证实了这一点。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/28b81eba2e15387ebf431cce2b895aba\" tg-width=\"600\" tg-height=\"371\" referrerpolicy=\"no-referrer\">Moderna Spikevax pricing tiers. Data source: Moderna</p><p><blockquote>Moderna Spikevax定价等级。数据来源：Moderna</blockquote></p><p> Moderna adopts a tiered pricing model to distribute its vaccines equitably. For the USG, the company has applied a \"favorable\" pricing model because of the US government's funding as well as the 500M doses order that the USG committed to Moderna, which the company emphasized, \"is very large.\"</p><p><blockquote>Moderna采用分级定价模式来公平分配其疫苗。对于美国政府来说，由于美国政府的资助以及美国政府向Moderna承诺的5亿剂订单，该公司采用了“有利”的定价模式，该公司强调该订单“非常大”。</blockquote></p><p></p><p> The other higher-income countries paid between $32 and $37, including larger orders from countries that include the EU with an APA of260M dosesfor 2021. Thus, applying Moderna's large contract discount logic, we should expect the average EU pricing to be at the lower end of the $32 to $37 range.</p><p><blockquote>其他高收入国家支付了32至37美元，其中包括来自欧盟等国家的更大订单，2021年APA为2.6亿剂。因此，应用Moderna的大合同折扣逻辑，我们应该预计欧盟平均定价将处于32美元至37美元范围的下限。</blockquote></p><p> For the lower to middle-income countries, even though the company did not explicitly disclose the exact price range, the company highlighted that this category \"received the lowest-tiered pricing, including those sales to COVAX, which are considerably lower than the price to the U.S. government.\"</p><p><blockquote>对于中低收入国家，尽管该公司没有明确披露确切的价格范围，但该公司强调，该类别“获得了最低等级的定价，包括向COVAX销售的产品，其价格远低于向美国政府。”</blockquote></p><p> For Moderna, we could easily derive its average price at about $19.7 ($5.93B/301M) per dose for H1'21, even though the company has emphasized that it's likely to be reduced moving into 2022 as they ramp the production for delivery to COVAX as well as the lower and middle-income countries, especially since the COVAX APA is set to increase from 34M doses in 2021 to 117M doses in 2022, with an option to increase up to 350M doses.</p><p><blockquote>对于Moderna来说，我们可以很容易地得出其H1'21的平均价格约为每剂19.7美元（59.3亿美元/3.01亿美元），尽管该公司强调，随着他们提高产量以交付给COVAX以及中低收入国家，特别是因为COVAX APA将从2021年的3400万剂增加到2022年的1.17亿剂，并可选择增加到3.5亿剂。</blockquote></p><p> COVAX reported an average price of about$5.20 per dose; thus, it would be useful for investors to continue monitoring the impact on the average price for mRNA-1273 moving forward. Moderna has also indicated that it is expecting more price competition as we move from a pandemic towards a world where COVID-19 is endemic. In addition, it may also be useful to watch closely for further improvement in its economies of scale as the company ramps production from an estimated 800M to 1B doses in 2021 to 2B to 3B doses in 2022.</p><p><blockquote>COVAX报告的平均价格约为每剂5.20美元；因此，投资者继续监测对mRNA-1273未来平均价格的影响将是有用的。Moderna还表示，随着我们从大流行转向新冠肺炎流行的世界，它预计会出现更多的价格竞争。此外，随着该公司将产量从2021年估计的8亿至10亿剂提高到2022年的20亿至30亿剂，密切关注其规模经济的进一步改善也可能是有用的。</blockquote></p><p> Moderna's Strategy Moving <a href=\"https://laohu8.com/S/FORD\">Forward</a></p><p><blockquote>Moderna的战略正在转变<a href=\"https://laohu8.com/S/FORD\">向前</a></blockquote></p><p> Share of the population fully vaccinated against COVID-19. Source: OWID</p><p><blockquote>完全接种新冠肺炎疫苗的人口比例。资料来源：OWID</blockquote></p><p> It's straightforward that Moderna has ramped production significantly to compete for the next phase in COVID-19 distribution for its mRNA-1273 product for countries within the COVAX category in 2022 and 2023 as the high-income countries are starting to approach the 60% to 70% fully vaccinated mark. However, we could clearly glean from the chart above where only 15% of the total world population has been fully vaccinated, while countries like Indonesia and India have only 8% and 7.8% of their population fully inoculated, and South America's 20.9% still has a long way to go as well.</p><p><blockquote>显而易见，随着高收入国家开始接近60%至70%，Moderna已大幅提高产量，以竞争2022年和2023年其mRNA-1273产品在COVAX类别国家的下一阶段COVID-19分销。完全接种疫苗的标记。然而，我们可以从上面的图表中清楚地收集到，世界总人口中只有15%的人完全接种了疫苗，而印度尼西亚和印度等国家只有8%和7.8%的人口完全接种了疫苗，南美洲的20.9%也还有很长的路要走。</blockquote></p><p> Moving forward, the strategy for the high-income countries is starting to move towards booster shots. We think this is where Moderna, as one of the 2 mRNA vaccines makers, has sufficiently proven its worth against <a href=\"https://laohu8.com/S/PFE\">Pfizer</a>-BioNTech as the company's recent COVE study demonstrated that mRNA-1273 could maintain the efficacy of 93.2%, 4 to 6 months after the second dose, and a 98.2% efficacy against severe disease, as well as a 100% efficacy against death caused by COVID-19. As compared to Pfizer-BioNTech's vaccine, where the efficacy is expected to drop to84%after 6 months, we would clearly applaud the breathtaking results that clearly demonstrate the superiority of Moderna's Spikevax against Comirnaty.</p><p><blockquote>展望未来，高收入国家的战略开始转向加强注射。我们认为，Moderna作为两家mRNA疫苗制造商之一，已经充分证明了其对抗的价值<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>-BioNTech as公司最近的COVE研究表明，mRNA-1273在第二剂后4至6个月可保持93.2%的疗效，对重症的疗效为98.2%，对新冠肺炎引起的死亡疗效为100%。与辉瑞-BioNTech的疫苗相比，预计6个月后疗效将降至84%，我们显然会对令人惊叹的结果表示赞赏，这些结果清楚地证明了Moderna的Spikevax相对于Comirnaty的优越性。</blockquote></p><p> To this Moderna Co-founder and Chairman Dr. Noubar Afeyan clearly articulated who he thinks owns the superior mRNA technology for COVID-19 vaccine in the market (shout-out to Pfizer-BioNTech folks):</p><p><blockquote>Moderna联合创始人兼董事长Noubar Afeyan博士明确阐述了他认为谁拥有市场上用于COVID-19疫苗的卓越mRNA技术（向辉瑞-BioNTech人员大喊）：</blockquote></p><p>   We set outto develop the most effective vaccine against this virus that would last for the longest possible time, [helping] the largest number of people to be safe...And this is the first time we had data that at least showed that six months after the initial vaccinations were seeing essentially the same level of protection, which is very encouraging.  Moderna also emphasized that we should never underestimate the efficacy differences as just plain numbers, which in Moderna's and Pfizer-BioNTech's case amounted to 9.2% points. The company emphasized that:</p><p><blockquote>我们着手开发针对这种病毒的最有效的疫苗，这种疫苗将持续尽可能长的时间，[帮助]最多的人获得安全...这是我们第一次有数据至少显示，在初次接种疫苗六个月后，保护水平基本相同，这非常令人鼓舞。Moderna还强调，我们永远不应该将疗效差异低估为简单的数字，在Moderna和辉瑞-BioNTech的案例中，疗效差异达9.2%。公司强调：</blockquote></p><p></p><p>   The relative strength of the different vaccines suggested that small differences in efficacy would start to emerge to be larger differences in efficacy at about 200, 250 days as neutralizing antibody titers waned. And that may be what we're starting to see. And if you play that forward, if you assume [Professor Davenport of the University of <a href=\"https://laohu8.com/S/NGD\">New</a> South Wales, Australia] been right about those predictions, then that picture continues and continues through a year with continued declining neutralizing antibody titers over that time. And eventually, we therefore believe, a real increase in breakthrough infections and disease even with vaccinated participants, even with mRNA-1273.  Moderna has also presented clear findings where it expects that a booster shot would significantly increase the neutralizing titers. In contrast, without the booster, for test subjects 6 to 8 months after their second dose, the neutralizing titers have dropped so significantly that for the Beta, Gamma and Delta variants, the \"neutralizing titers had fallen below the detectable -- the level of detection of the assay for a decent number of participants in all 4 -- all 3 cases.\"</p><p><blockquote>不同疫苗的相对强度表明，随着中和抗体滴度减弱，效力的小差异将在约200、250天时开始表现为效力的大差异。这可能是我们开始看到的。如果你扮演那个前锋，如果你假设[达文波特教授<a href=\"https://laohu8.com/S/NGD\">新的</a>澳大利亚南威尔士]的这些预测是正确的，然后这种情况会持续一年，在此期间中和抗体滴度持续下降。因此，我们相信，最终，即使是接种疫苗的参与者，即使是mRNA-1273，突破性感染和疾病也会真正增加。Moderna还提出了明确的发现，预计加强注射将显着增加中和滴度。相比之下，在没有加强剂的情况下，对于第二次给药后6至8个月的测试受试者，中和滴度显著下降，以至于对于β、γ和δ变体，“中和滴度已降至可检测水平以下——在所有4-所有3种情况下，相当数量的参与者的检测水平。”</blockquote></p><p> As a result, we expect Moderna has strongly assembled the case for a booster with strong evidence suggesting their importance to protect against the new potential variants that may emerge, which Moderna has certainly warned: \"...It seems logical to us that those 3 mutations present in the Beta, Gamma line and those 2 mutations present in the Delta might find some way to combine in new and potentially scary ways. And if that came with the increased transmissibility, [the] force of infection that Delta can achieve, that might be a significant threat. And so we view our multivalent platform as the best place for us to try and anticipate that threat.\"</p><p><blockquote>因此，我们预计Moderna已经强有力地组装了加强剂的案例，有强有力的证据表明它们对于防止可能出现的新的潜在变异的重要性，Moderna当然警告过：“...对我们来说，β、γ线中存在的3种突变和δ中存在的2种突变可能会找到某种方式以新的和潜在的可怕方式结合起来，这似乎是合乎逻辑的。如果这伴随着传播性的增加，德尔塔可以达到的感染强度，这可能是一个重大威胁。因此，我们认为我们的多价平台是我们尝试和预测这种威胁的最佳场所。”</blockquote></p><p> The company is developing a \"proactive\" multivalent platform where it combines \"different variants into a single vaccine\" as its strategy to combat potential variants that are expected to emerge. Based on the company's assays study, this platform clearly outperformed the other candidates in its study. In addition, it stood out as a strong candidate to be used as a booster option, even though the primary mRNA-1273 candidate can also be used effectively as a booster.</p><p><blockquote>该公司正在开发一种“主动”的多价平台，将“不同的变种组合成一种疫苗”，作为对抗预计出现的潜在变种的策略。根据该公司的检测研究，该平台在其研究中明显优于其他候选平台。此外，尽管初级mRNA-1273候选物也可以有效地用作加强剂，但它作为用作加强剂选项的有力候选物脱颖而出。</blockquote></p><p> However, in a fast-evolving situation with COVID-19, we think having more efficacious options are only going to be beneficial as vaccine makers try to anticipate and are proactive against potential new and more potent antigens where Moderna even admitted that the Delta variant had humbled them, as it added: \"I think the Delta variant has taught us to also be incredibly humble in the face of the virus' ability to fight back and increase its transmission. I mean, I think most of us would have thought SARS-CoV-2 was a pretty good infector earlier this year. Delta has shown us that it can make huge steps forward.\"</p><p><blockquote>然而，在COVID-19快速发展的情况下，我们认为拥有更有效的选择只会是有益的，因为疫苗制造商试图预测并积极对抗潜在的新的、更有效的抗原，Moderna甚至承认德尔塔变异毒株已经谦卑了他们，并补充道：“我认为德尔塔变异毒株教会了我们，面对病毒反击和增加传播的能力，也要非常谦卑。我的意思是，我认为我们大多数人今年早些时候都会认为新型冠状病毒是一个相当不错的感染者。达美航空向我们展示了它可以取得巨大的进步。”</blockquote></p><p> Risks to our Thesis</p><p><blockquote>我们论文的风险</blockquote></p><p> By now, it should be clear that 2022 is promising to be a year where Moderna would almost double or triple its supply to 2B or 3B doses, depending on whether the company is using 100 micrograms or 50 micrograms in its product moving forward. Pfizer-BioNTech is also expected to increase its capacity to 3B doses in 2022, while we also need to take into account Novavax's impending entry into the COVID-19 vaccines production game, as well as the Chinese vaccine makers who already have an annual capacity of 5B doses.</p><p><blockquote>到目前为止，应该很明显，2022年Moderna有望将其2B或3B剂量的供应量增加近一倍或三倍，这取决于该公司未来在其产品中使用100微克还是50微克。辉瑞-BioNTech预计也将在2022年将其产能提高到3B剂，同时我们还需要考虑到Novavax即将进入COVID-19疫苗生产游戏，以及已经拥有5B剂年产能的中国疫苗制造商。</blockquote></p><p> We think there is a realistic chance where Moderna may be facing an over-supply situation even though it may have proven itself to be the superior mRNA vaccine for now against Pfizer-BioNTech.</p><p><blockquote>我们认为Moderna很可能面临供应过剩的情况，尽管它可能已经证明自己是目前对抗辉瑞BioNTech的优质mRNA疫苗。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/3b54cee9edb8e398275290f3edcdb770\" tg-width=\"640\" tg-height=\"353\" referrerpolicy=\"no-referrer\">Revenue forecast mean consensus. Data source: S&amp;P Capital IQ</p><p><blockquote>收入预测意味着共识。数据来源：标普资本智商</blockquote></p><p> Therefore, we think the Street has prudently lowered its revenue estimates for Moderna over the next few years. The company is also likely to come under pricing pressure against the huge supply expected to come online.</p><p><blockquote>因此，我们认为华尔街谨慎地下调了Moderna未来几年的收入预期。由于预计将上线的大量供应，该公司也可能面临定价压力。</blockquote></p><p> However, we think Moderna is keenly aware of it. The company clearly highlighted that they had made good progress in the other 5 therapeutic areas that the company is involved in. Of notable mention is the fast track designation the company recently received from the US FDA for the company'sRSV vaccine candidate, mRNA-1345, especially when there is no approved RSV vaccine yet in the market.</p><p><blockquote>然而，我们认为Moderna敏锐地意识到了这一点。该公司明确强调，他们在该公司参与的其他5个治疗领域取得了良好进展。值得注意的是，该公司最近获得了美国FDA对该公司的RSV候选疫苗mRNA-1345的快速通道指定，特别是在市场上尚未批准的RSV疫苗的情况下。</blockquote></p><p> In addition, the company has also commenced on the Phase I/II study of its mRNA-1010 quadrivalent seasonal flu vaccine to target the seasonal flu market, where it's worth about $5B to $6B annually, according to Moderna's estimates, especially when the current flu vaccine efficacy is between 40% and 60% according toCDC data. Moderna expects its quadrivalent vaccine to be launched as early as 2023.</p><p><blockquote>此外，该公司还开始了其mRNA-1010四价季节性流感疫苗的I/II期研究，以瞄准季节性流感市场，根据Moderna的估计，季节性流感市场每年的价值约为50亿至60亿美元，特别是在目前的情况下根据CDC的数据，流感疫苗的效力在40%至60%之间。Moderna预计其四价疫苗最早将于2023年上市。</blockquote></p><p></p><p> Moderna is also expecting good results from its CMV vaccine, which is expected to be entering Phase III trials soon. It would also allow the company to tap into a market worth between $2B and $5B annually.</p><p><blockquote>Moderna还期待其CMV疫苗取得良好效果，预计很快将进入III期试验。这也将使该公司能够进入每年价值20亿美元至50亿美元的市场。</blockquote></p><p> Hence, we think that the company has been proactively working on the success of its mRNA-1273 to progress confidently along the other programs to sustain its commercial success beyond just being a COVID-19 vaccine maker. Therefore, we encourage investors to monitor its most advanced programs closely and keep pace with them moving forward.</p><p><blockquote>因此，我们认为该公司一直在积极致力于mRNA-1273的成功，以自信地推进其他项目，以维持其商业成功，而不仅仅是成为COVID-19疫苗制造商。因此，我们鼓励投资者密切关注其最先进的计划，并与他们保持同步。</blockquote></p><p> Valuations</p><p><blockquote>估值</blockquote></p><p> <img src=\"https://static.tigerbbs.com/69cb54a8282012f6cff4095f28e2a08f\" tg-width=\"640\" tg-height=\"176\" referrerpolicy=\"no-referrer\">Biotech peers valuation comp set. Source: TIKR</p><p><blockquote>生物技术同行估值比较集。来源：TIKR</blockquote></p><p> EV / Fwd Rev trend. Data source: S&amp;P Capital IQ</p><p><blockquote>EV/Fwd转速趋势。数据来源：标普资本智商</blockquote></p><p> Moderna is currently trading at an EV / Fwd Rev of about 8x, which interestingly comes in below its peers' mean multiple of 14.14x, where Moderna may look to be attractively valued. However, this assumes that Moderna can keep increasing its revenue strongly over the next few years, a point that we have raised previously may face significant headwinds ahead.</p><p><blockquote>Moderna目前的EV/Fwd Rev约为8倍，有趣的是，这低于同行14.14倍的平均倍数，而Moderna的估值可能看起来很有吸引力。然而，这是假设Moderna能够在未来几年内继续强劲增长其收入，我们之前提出的这一点可能会面临重大阻力。</blockquote></p><p> Importantly, we could see that based on the company's expected revenue moving forward, the company is not likely to see meaningful progress on its capital appreciation potential moving forward as its revenue multiple by the end of FY25 is expected to be about 14.6x, which is in line with the peers' mean multiple right now.</p><p><blockquote>重要的是，我们可以看到，根据该公司未来的预期收入，该公司未来的资本增值潜力不太可能取得有意义的进展，因为到2025财年末其收入倍数预计约为14.6倍，这与目前同行的平均倍数一致。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/a4cc567a1361ba17617927c47a803418\" tg-width=\"640\" tg-height=\"476\" referrerpolicy=\"no-referrer\">Street's mean price target. Source: TIKR</p><p><blockquote>Street的平均目标价。来源：TIKR</blockquote></p><p> Moreover, the Street is also not optimistic on MRNA making meaningful headway from here, and in fact, values the stock at about a 5.2x implied EV / Fwd Rev multiple, at a 35% discount from the last closing price. Analysts from <a href=\"https://laohu8.com/S/OPY\">Oppenheimer</a> also emphasized that \"MRNA sharesare fairly pricing a tremendous amount of future recurring revenues and pipeline progress...[arguing] that the company’s non-COVID pipeline remains 2-3 years away from reaching commercial success.\"</p><p><blockquote>此外，华尔街也不看好MRNA从这里取得有意义的进展，事实上，该股的估值约为隐含EV/Fwd Rev倍数的5.2倍，较上一收盘价折价35%。分析师来自<a href=\"https://laohu8.com/S/OPY\">奥本海默</a>还强调，“MRNA股票公平地定价了大量未来经常性收入和管道进展……[认为]该公司的非新冠管道距离取得商业成功还有2-3年的时间。”</blockquote></p><p> Our opinion is in line with the Street, and we think that a lot of optimism is currently being priced into Moderna at the moment. So we think if investors are sitting on decent profits right now, we strongly encourage you to at least take partial profits and take some risk off the table.</p><p><blockquote>我们的观点与华尔街的观点一致，我们认为Moderna目前的定价中包含了很多乐观情绪。因此，我们认为，如果投资者现在坐拥可观的利润，我们强烈建议您至少获利了结部分利润并消除一些风险。</blockquote></p><p> Price Action and Trend Analysis<img src=\"https://static.tigerbbs.com/766a37b6357b74ea899bd0e823ff64a2\" tg-width=\"640\" tg-height=\"391\" referrerpolicy=\"no-referrer\">Source: TradingView</p><p><blockquote>价格行为和趋势分析资料来源：TradingView</blockquote></p><p> While we are clear about MRNA's long-term uptrend bias (which is why we don't recommend a short-sell strategy against stocks with clear uptrend bias), we also think the stock's price action has recently shown signs of a climax top pattern.</p><p><blockquote>虽然我们清楚MRNA的长期上升趋势偏差（这就是为什么我们不建议对具有明显上升趋势偏差的股票采取卖空策略），但我们也认为该股的价格走势最近显示出高潮顶部模式的迹象。</blockquote></p><p> However, it's impossible to speculate exactly where the top is. Therefore, we think it's prudent for investors to take some profits off the table and wait for the euphoria to chill and cool down before considering adding exposure to MRNA again.</p><p><blockquote>然而，无法准确推测顶部在哪里。因此，我们认为投资者谨慎的做法是将部分利润撤出桌面，等待兴奋情绪降温后再考虑再次增加对MRNA的投资。</blockquote></p><p> We have already taken the opportunity of the stock's recent strength to lock in 50% of our profit on MRNA, with a view of locking in even more if we continue to see price action that shows a higher climax top tendency moving forward.</p><p><blockquote>我们已经利用该股近期走强的机会锁定了MRNA利润的50%，如果我们继续看到价格走势显示出更高的高潮顶部趋势，我们将锁定更多利润。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://seekingalpha.com/article/4447049-moderna-what-is-next-beyond-covid-vaccine-win\">seeking alpha</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://seekingalpha.com/article/4447049-moderna-what-is-next-beyond-covid-vaccine-win","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1109397612","content_text":"Investment Thesis\nModerna (MRNA) and Novavax (NVAX) released their respective Q2 earnings one after the other, with Moderna indicating encouraging progress in its mRNA vaccine programs along with its COVID-19 vaccine production ramp. At the same time, Novavax surprised the market with its delay in filing for emergency use authorization ((EUA)) with the US government ((USG)).\nModerna has continued to make excellent momentum as the company took full advantage of a highly successful COVID-19 vaccine program to develop the other vaccines in other therapeutic areas to future-proof its revenue sustainability, as the world gradually moves on to a world where COVID-19 is endemic.\nThis article provides a timely update for our readers to decide whether Moderna is still a good investment given the recent run-up that we think has resulted in a high amount of optimism being baked into its price.\nQ2 Earnings Recap\nModerna quarterly revenue surprise. Source: Seeking Alpha Premium\nModerna quarterly EPS surprise. Source: Seeking Alpha Premium\nModerna reported a solid Q2 report card, keeping in line with the momentum from Q1, as the company posted revenue of $4.354B and EPS of $6.46, which were 10.3% and 2.8% above the consensus estimates.\nModerna H1'21 revenue and FY21 consensus estimate. Data source: S&P Capital IQ\nImportantly, Moderna posted a highly impressive QoQ increase of 125% in revenue from $1.94B in Q1'21 to $4.35B in Q2'21. However, Moderna would need to significantly ramp up in H2'21 for the company to meet the Street's FY21 estimates as H1'21's revenue of $6.29B accounted for only 31.2% of the FY21 consensus estimates.\nTo that, Moderna has assured investors that based on the company's signed advanced purchase agreements ((APA)) for FY21, Moderna indicated that \"expected delivery in 2021reflect the current full-year total of approximately $20 billion in anticipated product sales.\" The company continues to anticipate a supply of at least 800M to 1B doses for 2021.\nStudying Moderna's Gross Margins and Pricing Strategy\nModerna quarterly gross margin. Data source: S&P Capital IQ\nThe production ramp in Q2'21 has also improved Moderna's economies of scale as its gross margin improved markedly in Q2'21, as Moderna's total cost of revenue represents about 26.9% of Q2'21 revenue.\nCrucially, Moderna has indicated that its COVID-19H1'21's product salesof $5.93B which constitute about 94.3% of H1'21's total revenue, has a much lower cost of revenue. Based on our findings, Moderna's COVID-19 product sales have a cost of revenue of $1.1B, representing about 18.5% of H1'21's COVID-19 product revenue, therefore indicating that the average gross margin for its COVID-19 product is about 81.5%. The company has also emphasized that it \"expects the average cost total of sales as a percent of product sales to be between 18% and 20% compared to our previous outlook of approximately 20% of product sales. This reflects the successful ramp-up of this global manufacturing network.\"\nSince Moderna delivered 199M doses in Q2'21 and 102M doses in Q1'21, the company delivered a collective amount of 301M doses in H1'21 that was recognized as product revenue. Given that our cost of revenue is about $1.1B for H1'21, we could thus derive an average cost per dose of about $3.65, which the company has highlighted that it expects to maintain for the rest of 2021.\nBefore we carry on, Moderna has highlighted that the cost of sales that the company reflected in H1'21 of $943M included their \"zero-cost COVID-19 inventory,\" as the company emphasized: \"At the end of the first quarter of 2021, we had substantially utilized our zero-cost COVID-19 vaccine inventory. Therefore, if inventory sold for the six months ended June 30, 2021, were valued at cost, our cost of sales for the period would have been $1.1 billion.\" Therefore, based on our computation above, we believe it's important to reflect the cost of sales more accurately, which the company also corroborates in their earnings call.\nModerna Spikevax pricing tiers. Data source: Moderna\nModerna adopts a tiered pricing model to distribute its vaccines equitably. For the USG, the company has applied a \"favorable\" pricing model because of the US government's funding as well as the 500M doses order that the USG committed to Moderna, which the company emphasized, \"is very large.\"\nThe other higher-income countries paid between $32 and $37, including larger orders from countries that include the EU with an APA of260M dosesfor 2021. Thus, applying Moderna's large contract discount logic, we should expect the average EU pricing to be at the lower end of the $32 to $37 range.\nFor the lower to middle-income countries, even though the company did not explicitly disclose the exact price range, the company highlighted that this category \"received the lowest-tiered pricing, including those sales to COVAX, which are considerably lower than the price to the U.S. government.\"\nFor Moderna, we could easily derive its average price at about $19.7 ($5.93B/301M) per dose for H1'21, even though the company has emphasized that it's likely to be reduced moving into 2022 as they ramp the production for delivery to COVAX as well as the lower and middle-income countries, especially since the COVAX APA is set to increase from 34M doses in 2021 to 117M doses in 2022, with an option to increase up to 350M doses.\nCOVAX reported an average price of about$5.20 per dose; thus, it would be useful for investors to continue monitoring the impact on the average price for mRNA-1273 moving forward. Moderna has also indicated that it is expecting more price competition as we move from a pandemic towards a world where COVID-19 is endemic. In addition, it may also be useful to watch closely for further improvement in its economies of scale as the company ramps production from an estimated 800M to 1B doses in 2021 to 2B to 3B doses in 2022.\nModerna's Strategy Moving Forward\nShare of the population fully vaccinated against COVID-19. Source: OWID\nIt's straightforward that Moderna has ramped production significantly to compete for the next phase in COVID-19 distribution for its mRNA-1273 product for countries within the COVAX category in 2022 and 2023 as the high-income countries are starting to approach the 60% to 70% fully vaccinated mark. However, we could clearly glean from the chart above where only 15% of the total world population has been fully vaccinated, while countries like Indonesia and India have only 8% and 7.8% of their population fully inoculated, and South America's 20.9% still has a long way to go as well.\nMoving forward, the strategy for the high-income countries is starting to move towards booster shots. We think this is where Moderna, as one of the 2 mRNA vaccines makers, has sufficiently proven its worth against Pfizer-BioNTech as the company's recent COVE study demonstrated that mRNA-1273 could maintain the efficacy of 93.2%, 4 to 6 months after the second dose, and a 98.2% efficacy against severe disease, as well as a 100% efficacy against death caused by COVID-19. As compared to Pfizer-BioNTech's vaccine, where the efficacy is expected to drop to84%after 6 months, we would clearly applaud the breathtaking results that clearly demonstrate the superiority of Moderna's Spikevax against Comirnaty.\nTo this Moderna Co-founder and Chairman Dr. Noubar Afeyan clearly articulated who he thinks owns the superior mRNA technology for COVID-19 vaccine in the market (shout-out to Pfizer-BioNTech folks):\n\n We set outto develop the most effective vaccine against this virus that would last for the longest possible time, [helping] the largest number of people to be safe...And this is the first time we had data that at least showed that six months after the initial vaccinations were seeing essentially the same level of protection, which is very encouraging.\n\nModerna also emphasized that we should never underestimate the efficacy differences as just plain numbers, which in Moderna's and Pfizer-BioNTech's case amounted to 9.2% points. The company emphasized that:\n\n The relative strength of the different vaccines suggested that small differences in efficacy would start to emerge to be larger differences in efficacy at about 200, 250 days as neutralizing antibody titers waned. And that may be what we're starting to see. And if you play that forward, if you assume [Professor Davenport of the University of New South Wales, Australia] been right about those predictions, then that picture continues and continues through a year with continued declining neutralizing antibody titers over that time. And eventually, we therefore believe, a real increase in breakthrough infections and disease even with vaccinated participants, even with mRNA-1273.\n\nModerna has also presented clear findings where it expects that a booster shot would significantly increase the neutralizing titers. In contrast, without the booster, for test subjects 6 to 8 months after their second dose, the neutralizing titers have dropped so significantly that for the Beta, Gamma and Delta variants, the \"neutralizing titers had fallen below the detectable -- the level of detection of the assay for a decent number of participants in all 4 -- all 3 cases.\"\nAs a result, we expect Moderna has strongly assembled the case for a booster with strong evidence suggesting their importance to protect against the new potential variants that may emerge, which Moderna has certainly warned: \"...It seems logical to us that those 3 mutations present in the Beta, Gamma line and those 2 mutations present in the Delta might find some way to combine in new and potentially scary ways. And if that came with the increased transmissibility, [the] force of infection that Delta can achieve, that might be a significant threat. And so we view our multivalent platform as the best place for us to try and anticipate that threat.\"\nThe company is developing a \"proactive\" multivalent platform where it combines \"different variants into a single vaccine\" as its strategy to combat potential variants that are expected to emerge. Based on the company's assays study, this platform clearly outperformed the other candidates in its study. In addition, it stood out as a strong candidate to be used as a booster option, even though the primary mRNA-1273 candidate can also be used effectively as a booster.\nHowever, in a fast-evolving situation with COVID-19, we think having more efficacious options are only going to be beneficial as vaccine makers try to anticipate and are proactive against potential new and more potent antigens where Moderna even admitted that the Delta variant had humbled them, as it added: \"I think the Delta variant has taught us to also be incredibly humble in the face of the virus' ability to fight back and increase its transmission. I mean, I think most of us would have thought SARS-CoV-2 was a pretty good infector earlier this year. Delta has shown us that it can make huge steps forward.\"\nRisks to our Thesis\nBy now, it should be clear that 2022 is promising to be a year where Moderna would almost double or triple its supply to 2B or 3B doses, depending on whether the company is using 100 micrograms or 50 micrograms in its product moving forward. Pfizer-BioNTech is also expected to increase its capacity to 3B doses in 2022, while we also need to take into account Novavax's impending entry into the COVID-19 vaccines production game, as well as the Chinese vaccine makers who already have an annual capacity of 5B doses.\nWe think there is a realistic chance where Moderna may be facing an over-supply situation even though it may have proven itself to be the superior mRNA vaccine for now against Pfizer-BioNTech.\nRevenue forecast mean consensus. Data source: S&P Capital IQ\nTherefore, we think the Street has prudently lowered its revenue estimates for Moderna over the next few years. The company is also likely to come under pricing pressure against the huge supply expected to come online.\nHowever, we think Moderna is keenly aware of it. The company clearly highlighted that they had made good progress in the other 5 therapeutic areas that the company is involved in. Of notable mention is the fast track designation the company recently received from the US FDA for the company'sRSV vaccine candidate, mRNA-1345, especially when there is no approved RSV vaccine yet in the market.\nIn addition, the company has also commenced on the Phase I/II study of its mRNA-1010 quadrivalent seasonal flu vaccine to target the seasonal flu market, where it's worth about $5B to $6B annually, according to Moderna's estimates, especially when the current flu vaccine efficacy is between 40% and 60% according toCDC data. Moderna expects its quadrivalent vaccine to be launched as early as 2023.\nModerna is also expecting good results from its CMV vaccine, which is expected to be entering Phase III trials soon. It would also allow the company to tap into a market worth between $2B and $5B annually.\nHence, we think that the company has been proactively working on the success of its mRNA-1273 to progress confidently along the other programs to sustain its commercial success beyond just being a COVID-19 vaccine maker. Therefore, we encourage investors to monitor its most advanced programs closely and keep pace with them moving forward.\nValuations\nBiotech peers valuation comp set. Source: TIKR\nEV / Fwd Rev trend. Data source: S&P Capital IQ\nModerna is currently trading at an EV / Fwd Rev of about 8x, which interestingly comes in below its peers' mean multiple of 14.14x, where Moderna may look to be attractively valued. However, this assumes that Moderna can keep increasing its revenue strongly over the next few years, a point that we have raised previously may face significant headwinds ahead.\nImportantly, we could see that based on the company's expected revenue moving forward, the company is not likely to see meaningful progress on its capital appreciation potential moving forward as its revenue multiple by the end of FY25 is expected to be about 14.6x, which is in line with the peers' mean multiple right now.\nStreet's mean price target. Source: TIKR\nMoreover, the Street is also not optimistic on MRNA making meaningful headway from here, and in fact, values the stock at about a 5.2x implied EV / Fwd Rev multiple, at a 35% discount from the last closing price. Analysts from Oppenheimer also emphasized that \"MRNA sharesare fairly pricing a tremendous amount of future recurring revenues and pipeline progress...[arguing] that the company’s non-COVID pipeline remains 2-3 years away from reaching commercial success.\"\nOur opinion is in line with the Street, and we think that a lot of optimism is currently being priced into Moderna at the moment. So we think if investors are sitting on decent profits right now, we strongly encourage you to at least take partial profits and take some risk off the table.\nPrice Action and Trend AnalysisSource: TradingView\nWhile we are clear about MRNA's long-term uptrend bias (which is why we don't recommend a short-sell strategy against stocks with clear uptrend bias), we also think the stock's price action has recently shown signs of a climax top pattern.\nHowever, it's impossible to speculate exactly where the top is. Therefore, we think it's prudent for investors to take some profits off the table and wait for the euphoria to chill and cool down before considering adding exposure to MRNA again.\nWe have already taken the opportunity of the stock's recent strength to lock in 50% of our profit on MRNA, with a view of locking in even more if we continue to see price action that shows a higher climax top tendency moving forward.","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":2198,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":898542626,"gmtCreate":1628514220865,"gmtModify":1633746555899,"author":{"id":"3564622621302285","authorId":"3564622621302285","name":"bluzon","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564622621302285","authorIdStr":"3564622621302285"},"themes":[],"htmlText":"[财迷]&nbsp;[财迷]&nbsp;[财迷]&nbsp;","listText":"[财迷]&nbsp;[财迷]&nbsp;[财迷]&nbsp;","text":"[财迷] [财迷] [财迷]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/898542626","repostId":"2158446563","repostType":4,"isVote":1,"tweetType":1,"viewCount":2638,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":154786939,"gmtCreate":1625545792021,"gmtModify":1633939773859,"author":{"id":"3564622621302285","authorId":"3564622621302285","name":"bluzon","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564622621302285","authorIdStr":"3564622621302285"},"themes":[],"htmlText":"Yeah.........","listText":"Yeah.........","text":"Yeah.........","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/154786939","repostId":"1116255026","repostType":4,"isVote":1,"tweetType":1,"viewCount":2994,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":154788047,"gmtCreate":1625545705189,"gmtModify":1633939774888,"author":{"id":"3564622621302285","authorId":"3564622621302285","name":"bluzon","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564622621302285","authorIdStr":"3564622621302285"},"themes":[],"htmlText":"[得意]&nbsp;[得意]&nbsp;[得意]&nbsp;[得意]&nbsp;[得意]&nbsp;[得意]&nbsp;","listText":"[得意]&nbsp;[得意]&nbsp;[得意]&nbsp;[得意]&nbsp;[得意]&nbsp;[得意]&nbsp;","text":"[得意] [得意] [得意] [得意] [得意] [得意]","images":[{"img":"https://static.tigerbbs.com/33e6ebf95ecbd05169befe8dd0a49dfc","width":"1080","height":"2986"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/154788047","isVote":1,"tweetType":1,"viewCount":1857,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":154039874,"gmtCreate":1625458967398,"gmtModify":1633940476216,"author":{"id":"3564622621302285","authorId":"3564622621302285","name":"bluzon","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564622621302285","authorIdStr":"3564622621302285"},"themes":[],"htmlText":"[得意]&nbsp;[得意]&nbsp;[得意]&nbsp;[得意]&nbsp;[得意]&nbsp;[得意]&nbsp;","listText":"[得意]&nbsp;[得意]&nbsp;[得意]&nbsp;[得意]&nbsp;[得意]&nbsp;[得意]&nbsp;","text":"[得意] [得意] [得意] [得意] [得意] [得意]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/154039874","repostId":"1169840279","repostType":4,"isVote":1,"tweetType":1,"viewCount":2190,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":154030209,"gmtCreate":1625458915501,"gmtModify":1633940476927,"author":{"id":"3564622621302285","authorId":"3564622621302285","name":"bluzon","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564622621302285","authorIdStr":"3564622621302285"},"themes":[],"htmlText":"[得意]&nbsp;[得意]&nbsp;[得意]&nbsp;[得意]&nbsp;[鬼脸]&nbsp;[鬼脸]&nbsp;[鬼脸]&nbsp;","listText":"[得意]&nbsp;[得意]&nbsp;[得意]&nbsp;[得意]&nbsp;[鬼脸]&nbsp;[鬼脸]&nbsp;[鬼脸]&nbsp;","text":"[得意] [得意] [得意] [得意] [鬼脸] [鬼脸] [鬼脸]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/154030209","repostId":"1169840279","repostType":4,"isVote":1,"tweetType":1,"viewCount":2886,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":154097783,"gmtCreate":1625458856542,"gmtModify":1633940477619,"author":{"id":"3564622621302285","authorId":"3564622621302285","name":"bluzon","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564622621302285","authorIdStr":"3564622621302285"},"themes":[],"htmlText":"[财迷]&nbsp;[财迷]&nbsp;[财迷]&nbsp;[财迷]&nbsp;","listText":"[财迷]&nbsp;[财迷]&nbsp;[财迷]&nbsp;[财迷]&nbsp;","text":"[财迷] [财迷] [财迷] [财迷]","images":[{"img":"https://static.tigerbbs.com/948a8e698190db45252b8d02957eab54","width":"1080","height":"3085"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/154097783","isVote":1,"tweetType":1,"viewCount":2548,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":151702121,"gmtCreate":1625105250863,"gmtModify":1633944744039,"author":{"id":"3564622621302285","authorId":"3564622621302285","name":"bluzon","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564622621302285","authorIdStr":"3564622621302285"},"themes":[],"htmlText":"[得意]&nbsp;[得意]&nbsp;[得意]&nbsp;[得意]&nbsp;[得意]&nbsp;[鬼脸]&nbsp;","listText":"[得意]&nbsp;[得意]&nbsp;[得意]&nbsp;[得意]&nbsp;[得意]&nbsp;[鬼脸]&nbsp;","text":"[得意] [得意] [得意] [得意] [得意] [鬼脸]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/151702121","repostId":"1178516480","repostType":4,"repost":{"id":"1178516480","kind":"news","pubTimestamp":1625094708,"share":"https://www.laohu8.com/m/news/1178516480?lang=zh_CN&edition=full","pubTime":"2021-07-01 07:11","market":"us","language":"en","title":"S&P 500 notches fifth straight record closing high, fifth straight quarterly gain<blockquote>标普500连续第五次创下收盘新高，连续第五个季度上涨</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1178516480","media":"Reuters","summary":"NEW YORK (Reuters) - The S&P 500 nabbed its fifth straight record closing high on Wednesday as inves","content":"<p>NEW YORK (Reuters) - The S&amp;P 500 nabbed its fifth straight record closing high on Wednesday as investors ended the month and the quarter by largely shrugging off positive economic data and looking toward Friday’s highly anticipated employment report.</p><p><blockquote>纽约（路透社）-标普500周三连续第五次创下收盘新高，投资者在本月和本季度结束时基本上摆脱了积极的经济数据，并期待周五备受期待的就业报告。</blockquote></p><p> In the last session of 2021’s first half, the indexes were languid and range-bound, with the blue-chip Dow posting gains, while the Nasdaq edged lower.</p><p><blockquote>在2021年上半年的最后一个交易日，股指低迷且区间震荡，蓝筹股道指上涨，而纳斯达克则小幅走低。</blockquote></p><p> All three indexes posted their fifth consecutive quarterly gains, with the S&amp;P rising 8.2%, the Nasdaq advancing 9.5% and the Dow rising 4.6%. The S&amp;P 500 registered its second-best first-half performance since 1998, rising 14.5%.</p><p><blockquote>三大指数均连续第五个季度上涨，标准普尔指数上涨8.2%，纳斯达克指数上涨9.5%，道指上涨4.6%。标普500上半年表现为1998年以来第二好，上涨14.5%。</blockquote></p><p> “It’s been a good quarter,” said Robert Pavlik, senior portfolio manager at Dakota Wealth in Fairfield, Connecticut. “As of last night’s close, the S&amp;P has gained more than 14% year-to-date, topping the Dow and the Nasdaq. That indicates that the stock market is having a broad rally.”</p><p><blockquote>“这是一个不错的季度，”康涅狄格州费尔菲尔德Dakota Wealth的高级投资组合经理罗伯特·帕夫利克(Robert Pavlik)表示。“截至昨晚收盘，标普今年迄今已上涨超过14%，超过道指和纳斯达克。这表明股市正在出现广泛反弹。”</blockquote></p><p> For the month, the bellwether S&amp;P 500 notched its fifth consecutive advance, while the Dow snapped its four-month winning streak to end slightly lower. The Nasdaq also gained ground in June.</p><p><blockquote>本月，领头羊标普500连续第五次上涨，而道琼斯指数结束了四个月的连涨，小幅收低。纳斯达克在6月份也取得了进展。</blockquote></p><p> This month, investor appetite shifted away from economically sensitive cyclicals in favor of growth stocks.</p><p><blockquote>本月，投资者的兴趣从对经济敏感的周期性股票转向成长型股票。</blockquote></p><p> “Leading sectors year-to-date are what you’d expect,” Pavlik added. “Energy, financials and industrials, and that speaks to an economic environment that’s in the early stages of a cycle.”</p><p><blockquote>“今年迄今为止的领先行业正如你所预期的那样，”帕夫利克补充道。“能源、金融和工业，这表明经济环境正处于周期的早期阶段。”</blockquote></p><p> “(Investors) started the switch back to growth (stocks) after people started to buy in to (Fed Chair Jerome) Powell’s comments that focus on transitory inflation,” Pavlik added.</p><p><blockquote>帕夫利克补充道：“在人们开始接受（美联储主席杰罗姆）鲍威尔关注暂时性通胀的言论后，（投资者）开始转向增长（股票）。”</blockquote></p><p> “Some of the reopening trades have gotten a bit long in the tooth and that’s leading people back to growth.”</p><p><blockquote>“一些重新开放的交易已经持续了一段时间，这正在引导人们恢复增长。”</blockquote></p><p> (Graphic: Growths stocks outperform value in June, narrow YTD gap, )</p><p><blockquote>（图：6月份成长股跑赢价值股，年初至今差距缩小，）</blockquote></p><p> <img src=\"https://static.tigerbbs.com/5b82b4dfdc765d913811f9d8572e60f6\" tg-width=\"964\" tg-height=\"723\" referrerpolicy=\"no-referrer\">“The overall stock market continues to be on a tear, with very consistent gains for quite some time,” said Tim Ghriskey, chief investment strategist at Inverness Counsel in New York. “Valuations, while certainly high by historical standards, have been at a fairly consistent level, benefiting from the economic recovery.”</p><p><blockquote>纽约Inverness Counsel首席投资策略师蒂姆·格里斯基(Tim Ghriskey)表示：“整体股市继续上涨，在相当长一段时间内持续上涨。”“虽然按照历史标准来看估值肯定很高，但受益于经济复苏，估值一直处于相当稳定的水平。”</blockquote></p><p> The private sector added 692,000 jobs in June, breezing past expectations, according to payroll processor ADP. The number is 92,000 higher than the private payroll adds economists predict from the Labor Department’s more comprehensive employment report due on Friday.</p><p><blockquote>根据薪资处理机构ADP的数据，私营部门6月份增加了692,000个就业岗位，轻松超出预期。这一数字比经济学家在劳工部周五发布的更全面的就业报告中预测的私人就业人数高出92,000人。</blockquote></p><p> The Dow Jones Industrial Average rose 210.22 points, or 0.61%, to 34,502.51, the S&amp;P 500 gained 5.7 points, or 0.13%, to 4,297.5 and the Nasdaq Composite dropped 24.38 points, or 0.17%, to 14,503.95.</p><p><blockquote>道琼斯工业平均指数上涨210.22点，涨幅0.61%，至34,502.51点；标普500上涨5.7点，涨幅0.13%，至4,297.5点；纳斯达克综合指数下跌24.38点，涨幅0.17%，至14,503.95点。</blockquote></p><p> Among the 11 major sectors in the S&amp;P, six ended the session higher, with energy enjoying the biggest percentage gain. Real estate was the day’s biggest loser.</p><p><blockquote>在标准普尔11个主要板块中，有6个板块收高，其中能源板块涨幅最大。房地产是当天最大的输家。</blockquote></p><p> Boeing Co gained 1.6% after Germany’s defense ministry announced it would buy five of the planemaker’s P-8A maritime control aircraft, coming on the heels of United Airlines unveiling its largest-ever order for new planes.</p><p><blockquote>德国国防部宣布将购买该飞机制造商的五架P-8A海上控制飞机，波音公司股价上涨1.6%，此前联合航空公布了有史以来最大的新飞机订单。</blockquote></p><p> Walmart jumped 2.7% after announcing on Tuesday that it would start selling a prescription-only insulin analog.</p><p><blockquote>沃尔玛周二宣布将开始销售仅限处方的胰岛素类似物，股价上涨2.7%。</blockquote></p><p> Micron Technology advanced 2.5% ahead of its quarterly earnings release, but was relatively unchanged in after-hours trading following the chipmaker’s quarterly results.</p><p><blockquote>美光科技在季度财报发布前上涨2.5%，但在芯片制造商公布季度业绩后，盘后交易中相对没有变化。</blockquote></p><p> Advancing issues outnumbered declining ones on the NYSE by a 1.35-to-1 ratio; on Nasdaq, a 1.19-to-1 ratio favored decliners.</p><p><blockquote>纽约证券交易所上涨股与下跌股的比例为1.35比1；在纳斯达克，1.19比1的比率有利于下跌股。</blockquote></p><p> The S&amp;P 500 posted 20 new 52-week highs and no new lows; the Nasdaq Composite recorded 70 new highs and 36 new lows.</p><p><blockquote>标普500创下20个52周新高，无新低；纳斯达克综合指数录得70个新高和36个新低。</blockquote></p><p> Volume on U.S. exchanges was 10.85 billion shares, compared with the 11.05 billion average over the last 20 trading days.</p><p><blockquote>美国交易所成交量为108.5亿股，而过去20个交易日的平均成交量为110.5亿股。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>S&P 500 notches fifth straight record closing high, fifth straight quarterly gain<blockquote>标普500连续第五次创下收盘新高，连续第五个季度上涨</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nS&P 500 notches fifth straight record closing high, fifth straight quarterly gain<blockquote>标普500连续第五次创下收盘新高，连续第五个季度上涨</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Reuters</strong><span class=\"h-time small\">2021-07-01 07:11</span>\n</p>\n</h4>\n</header>\n<article>\n<p>NEW YORK (Reuters) - The S&amp;P 500 nabbed its fifth straight record closing high on Wednesday as investors ended the month and the quarter by largely shrugging off positive economic data and looking toward Friday’s highly anticipated employment report.</p><p><blockquote>纽约（路透社）-标普500周三连续第五次创下收盘新高，投资者在本月和本季度结束时基本上摆脱了积极的经济数据，并期待周五备受期待的就业报告。</blockquote></p><p> In the last session of 2021’s first half, the indexes were languid and range-bound, with the blue-chip Dow posting gains, while the Nasdaq edged lower.</p><p><blockquote>在2021年上半年的最后一个交易日，股指低迷且区间震荡，蓝筹股道指上涨，而纳斯达克则小幅走低。</blockquote></p><p> All three indexes posted their fifth consecutive quarterly gains, with the S&amp;P rising 8.2%, the Nasdaq advancing 9.5% and the Dow rising 4.6%. The S&amp;P 500 registered its second-best first-half performance since 1998, rising 14.5%.</p><p><blockquote>三大指数均连续第五个季度上涨，标准普尔指数上涨8.2%，纳斯达克指数上涨9.5%，道指上涨4.6%。标普500上半年表现为1998年以来第二好，上涨14.5%。</blockquote></p><p> “It’s been a good quarter,” said Robert Pavlik, senior portfolio manager at Dakota Wealth in Fairfield, Connecticut. “As of last night’s close, the S&amp;P has gained more than 14% year-to-date, topping the Dow and the Nasdaq. That indicates that the stock market is having a broad rally.”</p><p><blockquote>“这是一个不错的季度，”康涅狄格州费尔菲尔德Dakota Wealth的高级投资组合经理罗伯特·帕夫利克(Robert Pavlik)表示。“截至昨晚收盘，标普今年迄今已上涨超过14%，超过道指和纳斯达克。这表明股市正在出现广泛反弹。”</blockquote></p><p> For the month, the bellwether S&amp;P 500 notched its fifth consecutive advance, while the Dow snapped its four-month winning streak to end slightly lower. The Nasdaq also gained ground in June.</p><p><blockquote>本月，领头羊标普500连续第五次上涨，而道琼斯指数结束了四个月的连涨，小幅收低。纳斯达克在6月份也取得了进展。</blockquote></p><p> This month, investor appetite shifted away from economically sensitive cyclicals in favor of growth stocks.</p><p><blockquote>本月，投资者的兴趣从对经济敏感的周期性股票转向成长型股票。</blockquote></p><p> “Leading sectors year-to-date are what you’d expect,” Pavlik added. “Energy, financials and industrials, and that speaks to an economic environment that’s in the early stages of a cycle.”</p><p><blockquote>“今年迄今为止的领先行业正如你所预期的那样，”帕夫利克补充道。“能源、金融和工业，这表明经济环境正处于周期的早期阶段。”</blockquote></p><p> “(Investors) started the switch back to growth (stocks) after people started to buy in to (Fed Chair Jerome) Powell’s comments that focus on transitory inflation,” Pavlik added.</p><p><blockquote>帕夫利克补充道：“在人们开始接受（美联储主席杰罗姆）鲍威尔关注暂时性通胀的言论后，（投资者）开始转向增长（股票）。”</blockquote></p><p> “Some of the reopening trades have gotten a bit long in the tooth and that’s leading people back to growth.”</p><p><blockquote>“一些重新开放的交易已经持续了一段时间，这正在引导人们恢复增长。”</blockquote></p><p> (Graphic: Growths stocks outperform value in June, narrow YTD gap, )</p><p><blockquote>（图：6月份成长股跑赢价值股，年初至今差距缩小，）</blockquote></p><p> <img src=\"https://static.tigerbbs.com/5b82b4dfdc765d913811f9d8572e60f6\" tg-width=\"964\" tg-height=\"723\" referrerpolicy=\"no-referrer\">“The overall stock market continues to be on a tear, with very consistent gains for quite some time,” said Tim Ghriskey, chief investment strategist at Inverness Counsel in New York. “Valuations, while certainly high by historical standards, have been at a fairly consistent level, benefiting from the economic recovery.”</p><p><blockquote>纽约Inverness Counsel首席投资策略师蒂姆·格里斯基(Tim Ghriskey)表示：“整体股市继续上涨，在相当长一段时间内持续上涨。”“虽然按照历史标准来看估值肯定很高，但受益于经济复苏，估值一直处于相当稳定的水平。”</blockquote></p><p> The private sector added 692,000 jobs in June, breezing past expectations, according to payroll processor ADP. The number is 92,000 higher than the private payroll adds economists predict from the Labor Department’s more comprehensive employment report due on Friday.</p><p><blockquote>根据薪资处理机构ADP的数据，私营部门6月份增加了692,000个就业岗位，轻松超出预期。这一数字比经济学家在劳工部周五发布的更全面的就业报告中预测的私人就业人数高出92,000人。</blockquote></p><p> The Dow Jones Industrial Average rose 210.22 points, or 0.61%, to 34,502.51, the S&amp;P 500 gained 5.7 points, or 0.13%, to 4,297.5 and the Nasdaq Composite dropped 24.38 points, or 0.17%, to 14,503.95.</p><p><blockquote>道琼斯工业平均指数上涨210.22点，涨幅0.61%，至34,502.51点；标普500上涨5.7点，涨幅0.13%，至4,297.5点；纳斯达克综合指数下跌24.38点，涨幅0.17%，至14,503.95点。</blockquote></p><p> Among the 11 major sectors in the S&amp;P, six ended the session higher, with energy enjoying the biggest percentage gain. Real estate was the day’s biggest loser.</p><p><blockquote>在标准普尔11个主要板块中，有6个板块收高，其中能源板块涨幅最大。房地产是当天最大的输家。</blockquote></p><p> Boeing Co gained 1.6% after Germany’s defense ministry announced it would buy five of the planemaker’s P-8A maritime control aircraft, coming on the heels of United Airlines unveiling its largest-ever order for new planes.</p><p><blockquote>德国国防部宣布将购买该飞机制造商的五架P-8A海上控制飞机，波音公司股价上涨1.6%，此前联合航空公布了有史以来最大的新飞机订单。</blockquote></p><p> Walmart jumped 2.7% after announcing on Tuesday that it would start selling a prescription-only insulin analog.</p><p><blockquote>沃尔玛周二宣布将开始销售仅限处方的胰岛素类似物，股价上涨2.7%。</blockquote></p><p> Micron Technology advanced 2.5% ahead of its quarterly earnings release, but was relatively unchanged in after-hours trading following the chipmaker’s quarterly results.</p><p><blockquote>美光科技在季度财报发布前上涨2.5%，但在芯片制造商公布季度业绩后，盘后交易中相对没有变化。</blockquote></p><p> Advancing issues outnumbered declining ones on the NYSE by a 1.35-to-1 ratio; on Nasdaq, a 1.19-to-1 ratio favored decliners.</p><p><blockquote>纽约证券交易所上涨股与下跌股的比例为1.35比1；在纳斯达克，1.19比1的比率有利于下跌股。</blockquote></p><p> The S&amp;P 500 posted 20 new 52-week highs and no new lows; the Nasdaq Composite recorded 70 new highs and 36 new lows.</p><p><blockquote>标普500创下20个52周新高，无新低；纳斯达克综合指数录得70个新高和36个新低。</blockquote></p><p> Volume on U.S. exchanges was 10.85 billion shares, compared with the 11.05 billion average over the last 20 trading days.</p><p><blockquote>美国交易所成交量为108.5亿股，而过去20个交易日的平均成交量为110.5亿股。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.reuters.com/article/us-usa-stocks/sp-500-notches-fifth-straight-record-closing-high-fifth-straight-quarterly-gain-idUSKCN2E619R\">Reuters</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯",".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite"},"source_url":"https://www.reuters.com/article/us-usa-stocks/sp-500-notches-fifth-straight-record-closing-high-fifth-straight-quarterly-gain-idUSKCN2E619R","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1178516480","content_text":"NEW YORK (Reuters) - The S&P 500 nabbed its fifth straight record closing high on Wednesday as investors ended the month and the quarter by largely shrugging off positive economic data and looking toward Friday’s highly anticipated employment report.\nIn the last session of 2021’s first half, the indexes were languid and range-bound, with the blue-chip Dow posting gains, while the Nasdaq edged lower.\nAll three indexes posted their fifth consecutive quarterly gains, with the S&P rising 8.2%, the Nasdaq advancing 9.5% and the Dow rising 4.6%. The S&P 500 registered its second-best first-half performance since 1998, rising 14.5%.\n“It’s been a good quarter,” said Robert Pavlik, senior portfolio manager at Dakota Wealth in Fairfield, Connecticut. “As of last night’s close, the S&P has gained more than 14% year-to-date, topping the Dow and the Nasdaq. That indicates that the stock market is having a broad rally.”\nFor the month, the bellwether S&P 500 notched its fifth consecutive advance, while the Dow snapped its four-month winning streak to end slightly lower. The Nasdaq also gained ground in June.\nThis month, investor appetite shifted away from economically sensitive cyclicals in favor of growth stocks.\n“Leading sectors year-to-date are what you’d expect,” Pavlik added. “Energy, financials and industrials, and that speaks to an economic environment that’s in the early stages of a cycle.”\n“(Investors) started the switch back to growth (stocks) after people started to buy in to (Fed Chair Jerome) Powell’s comments that focus on transitory inflation,” Pavlik added.\n“Some of the reopening trades have gotten a bit long in the tooth and that’s leading people back to growth.”\n(Graphic: Growths stocks outperform value in June, narrow YTD gap, )\n“The overall stock market continues to be on a tear, with very consistent gains for quite some time,” said Tim Ghriskey, chief investment strategist at Inverness Counsel in New York. “Valuations, while certainly high by historical standards, have been at a fairly consistent level, benefiting from the economic recovery.”\nThe private sector added 692,000 jobs in June, breezing past expectations, according to payroll processor ADP. The number is 92,000 higher than the private payroll adds economists predict from the Labor Department’s more comprehensive employment report due on Friday.\nThe Dow Jones Industrial Average rose 210.22 points, or 0.61%, to 34,502.51, the S&P 500 gained 5.7 points, or 0.13%, to 4,297.5 and the Nasdaq Composite dropped 24.38 points, or 0.17%, to 14,503.95.\nAmong the 11 major sectors in the S&P, six ended the session higher, with energy enjoying the biggest percentage gain. Real estate was the day’s biggest loser.\nBoeing Co gained 1.6% after Germany’s defense ministry announced it would buy five of the planemaker’s P-8A maritime control aircraft, coming on the heels of United Airlines unveiling its largest-ever order for new planes.\nWalmart jumped 2.7% after announcing on Tuesday that it would start selling a prescription-only insulin analog.\nMicron Technology advanced 2.5% ahead of its quarterly earnings release, but was relatively unchanged in after-hours trading following the chipmaker’s quarterly results.\nAdvancing issues outnumbered declining ones on the NYSE by a 1.35-to-1 ratio; on Nasdaq, a 1.19-to-1 ratio favored decliners.\nThe S&P 500 posted 20 new 52-week highs and no new lows; the Nasdaq Composite recorded 70 new highs and 36 new lows.\nVolume on U.S. exchanges was 10.85 billion shares, compared with the 11.05 billion average over the last 20 trading days.","news_type":1,"symbols_score_info":{".SPX":0.9,".IXIC":0.9,".DJI":0.9}},"isVote":1,"tweetType":1,"viewCount":2321,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":159967717,"gmtCreate":1624936952539,"gmtModify":1633946757606,"author":{"id":"3564622621302285","authorId":"3564622621302285","name":"bluzon","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564622621302285","authorIdStr":"3564622621302285"},"themes":[],"htmlText":"[财迷]&nbsp;[财迷]&nbsp;[财迷]&nbsp;","listText":"[财迷]&nbsp;[财迷]&nbsp;[财迷]&nbsp;","text":"[财迷] [财迷] [财迷]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/159967717","repostId":"2147837316","repostType":4,"isVote":1,"tweetType":1,"viewCount":2330,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":127110229,"gmtCreate":1624839215561,"gmtModify":1633948237177,"author":{"id":"3564622621302285","authorId":"3564622621302285","name":"bluzon","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564622621302285","authorIdStr":"3564622621302285"},"themes":[],"htmlText":"Yes........","listText":"Yes........","text":"Yes........","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/127110229","repostId":"2146007118","repostType":4,"isVote":1,"tweetType":1,"viewCount":1864,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":127135839,"gmtCreate":1624839126321,"gmtModify":1633948239928,"author":{"id":"3564622621302285","authorId":"3564622621302285","name":"bluzon","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564622621302285","authorIdStr":"3564622621302285"},"themes":[],"htmlText":"👍👍👍👍👍👍","listText":"👍👍👍👍👍👍","text":"👍👍👍👍👍👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/127135839","repostId":"1136989303","repostType":4,"isVote":1,"tweetType":1,"viewCount":612,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":124032106,"gmtCreate":1624705006805,"gmtModify":1633949414637,"author":{"id":"3564622621302285","authorId":"3564622621302285","name":"bluzon","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564622621302285","authorIdStr":"3564622621302285"},"themes":[],"htmlText":"🤑🤑🤑🤑","listText":"🤑🤑🤑🤑","text":"🤑🤑🤑🤑","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/124032106","repostId":"1108941456","repostType":4,"isVote":1,"tweetType":1,"viewCount":411,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":125987189,"gmtCreate":1624641522741,"gmtModify":1633950131304,"author":{"id":"3564622621302285","authorId":"3564622621302285","name":"bluzon","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564622621302285","authorIdStr":"3564622621302285"},"themes":[],"htmlText":"😅😅😅😅😅😅😅","listText":"😅😅😅😅😅😅😅","text":"😅😅😅😅😅😅😅","images":[{"img":"https://static.tigerbbs.com/cf2d2d06c681ed071c837b2c6ded149c","width":"1080","height":"2986"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/125987189","isVote":1,"tweetType":1,"viewCount":376,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":125984944,"gmtCreate":1624641478088,"gmtModify":1633950131978,"author":{"id":"3564622621302285","authorId":"3564622621302285","name":"bluzon","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564622621302285","authorIdStr":"3564622621302285"},"themes":[],"htmlText":"🌈🌈🌈","listText":"🌈🌈🌈","text":"🌈🌈🌈","images":[{"img":"https://static.tigerbbs.com/9bfd66d7434fdadbc3299e41df064612","width":"1080","height":"2986"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/125984944","isVote":1,"tweetType":1,"viewCount":680,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":125988755,"gmtCreate":1624641326877,"gmtModify":1633950133419,"author":{"id":"3564622621302285","authorId":"3564622621302285","name":"bluzon","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564622621302285","authorIdStr":"3564622621302285"},"themes":[],"htmlText":"☺","listText":"☺","text":"☺","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/125988755","repostId":"2146079086","repostType":4,"isVote":1,"tweetType":1,"viewCount":479,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":169188716,"gmtCreate":1623821697835,"gmtModify":1634027550501,"author":{"id":"3564622621302285","authorId":"3564622621302285","name":"bluzon","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564622621302285","authorIdStr":"3564622621302285"},"themes":[],"htmlText":"Gd","listText":"Gd","text":"Gd","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/169188716","repostId":"1128132038","repostType":4,"isVote":1,"tweetType":1,"viewCount":922,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":185819610,"gmtCreate":1623640523730,"gmtModify":1634030784146,"author":{"id":"3564622621302285","authorId":"3564622621302285","name":"bluzon","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564622621302285","authorIdStr":"3564622621302285"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/185819610","repostId":"1123083008","repostType":4,"isVote":1,"tweetType":1,"viewCount":610,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":185810659,"gmtCreate":1623640491671,"gmtModify":1634030784961,"author":{"id":"3564622621302285","authorId":"3564622621302285","name":"bluzon","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564622621302285","authorIdStr":"3564622621302285"},"themes":[],"htmlText":"Yeahs&nbsp;","listText":"Yeahs&nbsp;","text":"Yeahs","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/185810659","repostId":"1146011836","repostType":4,"isVote":1,"tweetType":1,"viewCount":496,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":183307336,"gmtCreate":1623305054225,"gmtModify":1634034750712,"author":{"id":"3564622621302285","authorId":"3564622621302285","name":"bluzon","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564622621302285","authorIdStr":"3564622621302285"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/183307336","repostId":"2142241696","repostType":4,"isVote":1,"tweetType":1,"viewCount":355,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":183307078,"gmtCreate":1623305013594,"gmtModify":1634034750834,"author":{"id":"3564622621302285","authorId":"3564622621302285","name":"bluzon","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564622621302285","authorIdStr":"3564622621302285"},"themes":[],"htmlText":"OK&nbsp;","listText":"OK&nbsp;","text":"OK","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/183307078","repostId":"2142241696","repostType":4,"isVote":1,"tweetType":1,"viewCount":569,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":159967717,"gmtCreate":1624936952539,"gmtModify":1633946757606,"author":{"id":"3564622621302285","authorId":"3564622621302285","name":"bluzon","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3564622621302285","idStr":"3564622621302285"},"themes":[],"htmlText":"[财迷]&nbsp;[财迷]&nbsp;[财迷]&nbsp;","listText":"[财迷]&nbsp;[财迷]&nbsp;[财迷]&nbsp;","text":"[财迷] [财迷] [财迷]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/159967717","repostId":"2147837316","repostType":4,"isVote":1,"tweetType":1,"viewCount":2330,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":185819610,"gmtCreate":1623640523730,"gmtModify":1634030784146,"author":{"id":"3564622621302285","authorId":"3564622621302285","name":"bluzon","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3564622621302285","idStr":"3564622621302285"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/185819610","repostId":"1123083008","repostType":4,"repost":{"id":"1123083008","kind":"news","pubTimestamp":1623638943,"share":"https://www.laohu8.com/m/news/1123083008?lang=zh_CN&edition=full","pubTime":"2021-06-14 10:49","market":"us","language":"en","title":"Is fuboTV at Risk From This World Cup Controversy?<blockquote>富波电视是否因这场世界杯争议而面临风险？</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1123083008","media":"Motley Fool ","summary":"A change of venue and skittish advertisers make it a volatile situation.","content":"<p><b>fuboTV</b>&nbsp;(NYSE:FUBO)&nbsp;has a lot riding on the&nbsp;Qatar World Cup qualifying games&nbsp;that kicked off on June 3.</p><p><blockquote><b>富波电视</b>（纽约证券交易所股票代码：FUBO）对6月3日拉开帷幕的卡塔尔世界杯预选赛有很大影响。</blockquote></p><p> As the exclusive rights holder to livestream the 70 soccer matches of the South American Football Confederation, also known as CONMEBOL, the sports livestreaming platform has an opportunity to get tens of millions of new fans to sign up for its service.</p><p><blockquote>作为南美足球联合会（也称为CONMEBOL）70场足球比赛的独家直播权持有者，体育直播平台有机会吸引数千万新球迷注册其服务。</blockquote></p><p> With fuboTV's plans to launch a new sports betting platform later this year and seamlessly blend the two operations into a cohesive whole, the qualifying matches represent a huge revenue opportunity.</p><p><blockquote>富波电视计划在今年晚些时候推出一个新的体育博彩平台，并将两项业务无缝融合为一个有凝聚力的整体，资格赛代表着巨大的收入机会。</blockquote></p><p> Yet controversy over where the Copa America portion of the games will be played could upset those plans.</p><p><blockquote>然而，关于美洲杯部分比赛将在哪里举行的争议可能会打乱这些计划。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/d9190055f7e0a3f2296dd635294f7598\" tg-width=\"2000\" tg-height=\"1333\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图片来源：盖蒂图片社。</span></p></blockquote></p><p> A country at risk</p><p><blockquote>处于危险中的国家</blockquote></p><p> Copa America is the oldest and arguably most prestigious football competition of national teams. Started in 1910 as part of celebrations around Argentina's independence, Chile, Uruguay, and Brazil also participated.</p><p><blockquote>美洲杯是最古老也可以说是最负盛名的国家队足球比赛。始于1910年，作为阿根廷独立庆祝活动的一部分，智利、乌拉圭和巴西也参加了。</blockquote></p><p> Back then, the tournament was called the Campeonato Sudamericano de Selecciones, but it changed to Copa America in 1975 and in 1993 began inviting teams from outside South America to compete. The U.S. and Mexico were the first teams permitted entry, though no outside club has ever won the tournaments.</p><p><blockquote>当时，这项赛事被称为Campeonato Sudamericano de Selecciones，但在1975年改为美洲杯，并于1993年开始邀请南美洲以外的球队参赛。美国和墨西哥是第一批被允许参赛的球队，尽管没有外部俱乐部赢得过比赛。</blockquote></p><p> This year Copa America was to be co-hosted by Columbia and Argentina, but CONMEBOL pulled the 10-nation games from Columbia because of civil unrest and Argentina backed out because of a spike in coronavirus cases.</p><p><blockquote>今年的美洲杯原定由哥伦比亚和阿根廷共同主办，但由于内乱，南美足联取消了哥伦比亚的10国运动会，阿根廷则因冠状病毒病例激增而退出。</blockquote></p><p> CONMEBOL chose Brazil as the location of the games, but an outcry arose over the country's choice because of the large number of COVID-19 deaths that have occurred there, some 479,000, which is second only to the U.S.</p><p><blockquote>CONMEBOL选择巴西作为奥运会举办地，但该国的选择引起了强烈抗议，因为那里发生了大量COVID-19死亡病例，约为479,000人，仅次于美国。</blockquote></p><p> With players complaining about the location choice, multinational companies began dropping their sponsorship of the games, potentially undermining the games and putting fuboTV's opportunity in jeopardy.</p><p><blockquote>随着玩家对地点选择的抱怨，跨国公司开始放弃对奥运会的赞助，这可能会破坏奥运会，并使fuboTV的机会处于危险之中。</blockquote></p><p> <b>A case of cold feet</b></p><p><blockquote><b>临阵退缩一例</b></blockquote></p><p> <b>AmBev</b>&nbsp;(NYSE:ABEV), the Brazilian unit of&nbsp;<b>Anheuser-Busch InBev</b>&nbsp;(NYSE:BUD)and sponsor of the Brazilian national team, announced \"its brands will not be present at the Copa America,\" as did&nbsp;<b>Mastercard</b>&nbsp;(NYSE:MA), which said it would not \"activate\" its sponsorship of the games, something it has done since 1992.</p><p><blockquote><b>安贝夫</b>（纽约证券交易所代码：ABEV），巴西子公司<b>百威英博</b>（纽约证券交易所股票代码：BUD）和巴西国家队赞助商宣布“其品牌将不会出现在美洲杯上”<b>万事达卡</b>（纽约证券交易所代码：MA）表示不会“激活”对奥运会的赞助，这是自1992年以来一直在做的事情。</blockquote></p><p> That was followed by global spirits distributor&nbsp;<b>Diageo</b>&nbsp;(NYSE:DEO), which said it was withdrawing sponsorship of Copa America \"given the current Brazilian health situation and out of respect for this moment of the COVID-19 pandemic.\"</p><p><blockquote>其次是全球烈酒经销商<b>帝亚吉欧</b>（纽约证券交易所股票代码：DEO）表示，“鉴于巴西目前的健康状况以及出于对COVID-19大流行这一时刻的尊重”，将撤回对美洲杯的赞助。</blockquote></p><p> Parties have gone to court to try to block Brazil from hosting the games, but the country's Supreme Court rejected the injunction bids and said the games could proceed, though they ordered various health and safety measures be implemented.</p><p><blockquote>各方已诉诸法院，试图阻止巴西举办奥运会，但该国最高法院驳回了禁令申请，并表示奥运会可以继续进行，尽管他们下令实施各种健康和安全措施。</blockquote></p><p> There also don't seem to be any boycotts of the games yet. While the Brazilian national team had called out \"humanitarian\" concerns over locating the games in their home country, it said it would still play.</p><p><blockquote>似乎也没有任何对奥运会的抵制。尽管巴西国家队对在自己的国家举办比赛表示了“人道主义”担忧，但它表示仍将参加比赛。</blockquote></p><p> <b>An exclusive opportunity</b></p><p><blockquote><b>独家机会</b></blockquote></p><p> This is why the qualifying games are so critical for fuboTV. To contain the possible spread of COVID-19, Brazilian officials are holding the games without fans present in the stadium, and the teams will undergo testing every 48 hours. Players will also have their movements restricted as they travel between the four host cities.</p><p><blockquote>这就是资格赛对fuboTV如此重要的原因。为了遏制新冠肺炎病毒可能的传播，巴西官员在没有球迷在场的情况下举行比赛，球队将每48小时接受一次检测。当玩家在四个主办城市之间旅行时，他们的行动也将受到限制。</blockquote></p><p> That means fans will need to find alternative means of watching the games, and with the sporting event's huge global popularity, fuboTV has a unique opportunity to see a massive influx of new subscribers to its&nbsp;streaming service.</p><p><blockquote>这意味着球迷需要找到观看比赛的替代方式，随着这项体育赛事在全球的巨大人气，fuboTV有一个独特的机会看到大量新订户涌入其流媒体服务。</blockquote></p><p> Select English-language games will be available to subscribers who have the fubo Sports Network, but they will only be available on fuboTV and not through the network's usual off-platform distribution partners, such as&nbsp;<b>ViacomCBS</b>' Pluto TV.</p><p><blockquote>拥有fubo Sports Network的订阅者将可以观看部分英语比赛，但这些比赛只能在fuboTV上观看，而不能通过该网络通常的平台外发行合作伙伴观看，例如<b>ViacomCBS</b>冥王星电视。</blockquote></p><p> The Copa America games will be free to current fuboTV subscribers, while new subscribers need to sign up for one of fubo's plans and then add the CONMEBOL &amp; More package for an additional $7 per month. That package includes eight other premium sports channels featuring soccer, baseball, football, basketball, and more.</p><p><blockquote>美洲杯比赛将对目前的富波电视订户免费，而新订户需要注册富波的一个计划，然后每月额外支付7美元添加CONMEBOL&amp;More套餐。该套餐包括其他八个优质体育频道，包括足球、棒球、橄榄球、篮球等。</blockquote></p><p> <b>It's still game on</b></p><p><blockquote><b>游戏还在继续</b></blockquote></p><p> fuboTV looks like it will avoid a collapse of the Copa America games, though other CONMEBOL games are going off without a hitch so far. As long as other major sponsors stay put, the teams don't boycott, and there are no COVID-19 outbreaks among players, it should be a success.</p><p><blockquote>富波电视看起来将避免美洲杯比赛的崩溃，尽管其他CONMEBOL比赛到目前为止进展顺利。只要其他主要赞助商留在原地，球队不抵制，球员中没有新冠肺炎疫情，这应该是成功的。</blockquote></p><p> The situation, though, shows just how fragile the sporting world still is as it emerges from the pandemic and tries returning to a sense of normalcy. fuboTV, though, still has&nbsp;enormous growth prospects&nbsp;before it.</p><p><blockquote>然而，这种情况表明，当体育界走出疫情并试图恢复正常时，它仍然是多么脆弱。不过，fuboTV仍有巨大的增长前景。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is fuboTV at Risk From This World Cup Controversy?<blockquote>富波电视是否因这场世界杯争议而面临风险？</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs fuboTV at Risk From This World Cup Controversy?<blockquote>富波电视是否因这场世界杯争议而面临风险？</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Motley Fool </strong><span class=\"h-time small\">2021-06-14 10:49</span>\n</p>\n</h4>\n</header>\n<article>\n<p><b>fuboTV</b>&nbsp;(NYSE:FUBO)&nbsp;has a lot riding on the&nbsp;Qatar World Cup qualifying games&nbsp;that kicked off on June 3.</p><p><blockquote><b>富波电视</b>（纽约证券交易所股票代码：FUBO）对6月3日拉开帷幕的卡塔尔世界杯预选赛有很大影响。</blockquote></p><p> As the exclusive rights holder to livestream the 70 soccer matches of the South American Football Confederation, also known as CONMEBOL, the sports livestreaming platform has an opportunity to get tens of millions of new fans to sign up for its service.</p><p><blockquote>作为南美足球联合会（也称为CONMEBOL）70场足球比赛的独家直播权持有者，体育直播平台有机会吸引数千万新球迷注册其服务。</blockquote></p><p> With fuboTV's plans to launch a new sports betting platform later this year and seamlessly blend the two operations into a cohesive whole, the qualifying matches represent a huge revenue opportunity.</p><p><blockquote>富波电视计划在今年晚些时候推出一个新的体育博彩平台，并将两项业务无缝融合为一个有凝聚力的整体，资格赛代表着巨大的收入机会。</blockquote></p><p> Yet controversy over where the Copa America portion of the games will be played could upset those plans.</p><p><blockquote>然而，关于美洲杯部分比赛将在哪里举行的争议可能会打乱这些计划。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/d9190055f7e0a3f2296dd635294f7598\" tg-width=\"2000\" tg-height=\"1333\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图片来源：盖蒂图片社。</span></p></blockquote></p><p> A country at risk</p><p><blockquote>处于危险中的国家</blockquote></p><p> Copa America is the oldest and arguably most prestigious football competition of national teams. Started in 1910 as part of celebrations around Argentina's independence, Chile, Uruguay, and Brazil also participated.</p><p><blockquote>美洲杯是最古老也可以说是最负盛名的国家队足球比赛。始于1910年，作为阿根廷独立庆祝活动的一部分，智利、乌拉圭和巴西也参加了。</blockquote></p><p> Back then, the tournament was called the Campeonato Sudamericano de Selecciones, but it changed to Copa America in 1975 and in 1993 began inviting teams from outside South America to compete. The U.S. and Mexico were the first teams permitted entry, though no outside club has ever won the tournaments.</p><p><blockquote>当时，这项赛事被称为Campeonato Sudamericano de Selecciones，但在1975年改为美洲杯，并于1993年开始邀请南美洲以外的球队参赛。美国和墨西哥是第一批被允许参赛的球队，尽管没有外部俱乐部赢得过比赛。</blockquote></p><p> This year Copa America was to be co-hosted by Columbia and Argentina, but CONMEBOL pulled the 10-nation games from Columbia because of civil unrest and Argentina backed out because of a spike in coronavirus cases.</p><p><blockquote>今年的美洲杯原定由哥伦比亚和阿根廷共同主办，但由于内乱，南美足联取消了哥伦比亚的10国运动会，阿根廷则因冠状病毒病例激增而退出。</blockquote></p><p> CONMEBOL chose Brazil as the location of the games, but an outcry arose over the country's choice because of the large number of COVID-19 deaths that have occurred there, some 479,000, which is second only to the U.S.</p><p><blockquote>CONMEBOL选择巴西作为奥运会举办地，但该国的选择引起了强烈抗议，因为那里发生了大量COVID-19死亡病例，约为479,000人，仅次于美国。</blockquote></p><p> With players complaining about the location choice, multinational companies began dropping their sponsorship of the games, potentially undermining the games and putting fuboTV's opportunity in jeopardy.</p><p><blockquote>随着玩家对地点选择的抱怨，跨国公司开始放弃对奥运会的赞助，这可能会破坏奥运会，并使fuboTV的机会处于危险之中。</blockquote></p><p> <b>A case of cold feet</b></p><p><blockquote><b>临阵退缩一例</b></blockquote></p><p> <b>AmBev</b>&nbsp;(NYSE:ABEV), the Brazilian unit of&nbsp;<b>Anheuser-Busch InBev</b>&nbsp;(NYSE:BUD)and sponsor of the Brazilian national team, announced \"its brands will not be present at the Copa America,\" as did&nbsp;<b>Mastercard</b>&nbsp;(NYSE:MA), which said it would not \"activate\" its sponsorship of the games, something it has done since 1992.</p><p><blockquote><b>安贝夫</b>（纽约证券交易所代码：ABEV），巴西子公司<b>百威英博</b>（纽约证券交易所股票代码：BUD）和巴西国家队赞助商宣布“其品牌将不会出现在美洲杯上”<b>万事达卡</b>（纽约证券交易所代码：MA）表示不会“激活”对奥运会的赞助，这是自1992年以来一直在做的事情。</blockquote></p><p> That was followed by global spirits distributor&nbsp;<b>Diageo</b>&nbsp;(NYSE:DEO), which said it was withdrawing sponsorship of Copa America \"given the current Brazilian health situation and out of respect for this moment of the COVID-19 pandemic.\"</p><p><blockquote>其次是全球烈酒经销商<b>帝亚吉欧</b>（纽约证券交易所股票代码：DEO）表示，“鉴于巴西目前的健康状况以及出于对COVID-19大流行这一时刻的尊重”，将撤回对美洲杯的赞助。</blockquote></p><p> Parties have gone to court to try to block Brazil from hosting the games, but the country's Supreme Court rejected the injunction bids and said the games could proceed, though they ordered various health and safety measures be implemented.</p><p><blockquote>各方已诉诸法院，试图阻止巴西举办奥运会，但该国最高法院驳回了禁令申请，并表示奥运会可以继续进行，尽管他们下令实施各种健康和安全措施。</blockquote></p><p> There also don't seem to be any boycotts of the games yet. While the Brazilian national team had called out \"humanitarian\" concerns over locating the games in their home country, it said it would still play.</p><p><blockquote>似乎也没有任何对奥运会的抵制。尽管巴西国家队对在自己的国家举办比赛表示了“人道主义”担忧，但它表示仍将参加比赛。</blockquote></p><p> <b>An exclusive opportunity</b></p><p><blockquote><b>独家机会</b></blockquote></p><p> This is why the qualifying games are so critical for fuboTV. To contain the possible spread of COVID-19, Brazilian officials are holding the games without fans present in the stadium, and the teams will undergo testing every 48 hours. Players will also have their movements restricted as they travel between the four host cities.</p><p><blockquote>这就是资格赛对fuboTV如此重要的原因。为了遏制新冠肺炎病毒可能的传播，巴西官员在没有球迷在场的情况下举行比赛，球队将每48小时接受一次检测。当玩家在四个主办城市之间旅行时，他们的行动也将受到限制。</blockquote></p><p> That means fans will need to find alternative means of watching the games, and with the sporting event's huge global popularity, fuboTV has a unique opportunity to see a massive influx of new subscribers to its&nbsp;streaming service.</p><p><blockquote>这意味着球迷需要找到观看比赛的替代方式，随着这项体育赛事在全球的巨大人气，fuboTV有一个独特的机会看到大量新订户涌入其流媒体服务。</blockquote></p><p> Select English-language games will be available to subscribers who have the fubo Sports Network, but they will only be available on fuboTV and not through the network's usual off-platform distribution partners, such as&nbsp;<b>ViacomCBS</b>' Pluto TV.</p><p><blockquote>拥有fubo Sports Network的订阅者将可以观看部分英语比赛，但这些比赛只能在fuboTV上观看，而不能通过该网络通常的平台外发行合作伙伴观看，例如<b>ViacomCBS</b>冥王星电视。</blockquote></p><p> The Copa America games will be free to current fuboTV subscribers, while new subscribers need to sign up for one of fubo's plans and then add the CONMEBOL &amp; More package for an additional $7 per month. That package includes eight other premium sports channels featuring soccer, baseball, football, basketball, and more.</p><p><blockquote>美洲杯比赛将对目前的富波电视订户免费，而新订户需要注册富波的一个计划，然后每月额外支付7美元添加CONMEBOL&amp;More套餐。该套餐包括其他八个优质体育频道，包括足球、棒球、橄榄球、篮球等。</blockquote></p><p> <b>It's still game on</b></p><p><blockquote><b>游戏还在继续</b></blockquote></p><p> fuboTV looks like it will avoid a collapse of the Copa America games, though other CONMEBOL games are going off without a hitch so far. As long as other major sponsors stay put, the teams don't boycott, and there are no COVID-19 outbreaks among players, it should be a success.</p><p><blockquote>富波电视看起来将避免美洲杯比赛的崩溃，尽管其他CONMEBOL比赛到目前为止进展顺利。只要其他主要赞助商留在原地，球队不抵制，球员中没有新冠肺炎疫情，这应该是成功的。</blockquote></p><p> The situation, though, shows just how fragile the sporting world still is as it emerges from the pandemic and tries returning to a sense of normalcy. fuboTV, though, still has&nbsp;enormous growth prospects&nbsp;before it.</p><p><blockquote>然而，这种情况表明，当体育界走出疫情并试图恢复正常时，它仍然是多么脆弱。不过，fuboTV仍有巨大的增长前景。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/06/13/is-fubotv-at-risk-from-this-world-cup-controversy/\">Motley Fool </a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FUBO":"fuboTV Inc."},"source_url":"https://www.fool.com/investing/2021/06/13/is-fubotv-at-risk-from-this-world-cup-controversy/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1123083008","content_text":"fuboTV (NYSE:FUBO) has a lot riding on the Qatar World Cup qualifying games that kicked off on June 3.\nAs the exclusive rights holder to livestream the 70 soccer matches of the South American Football Confederation, also known as CONMEBOL, the sports livestreaming platform has an opportunity to get tens of millions of new fans to sign up for its service.\nWith fuboTV's plans to launch a new sports betting platform later this year and seamlessly blend the two operations into a cohesive whole, the qualifying matches represent a huge revenue opportunity.\nYet controversy over where the Copa America portion of the games will be played could upset those plans.\nIMAGE SOURCE: GETTY IMAGES.\nA country at risk\nCopa America is the oldest and arguably most prestigious football competition of national teams. Started in 1910 as part of celebrations around Argentina's independence, Chile, Uruguay, and Brazil also participated.\nBack then, the tournament was called the Campeonato Sudamericano de Selecciones, but it changed to Copa America in 1975 and in 1993 began inviting teams from outside South America to compete. The U.S. and Mexico were the first teams permitted entry, though no outside club has ever won the tournaments.\nThis year Copa America was to be co-hosted by Columbia and Argentina, but CONMEBOL pulled the 10-nation games from Columbia because of civil unrest and Argentina backed out because of a spike in coronavirus cases.\nCONMEBOL chose Brazil as the location of the games, but an outcry arose over the country's choice because of the large number of COVID-19 deaths that have occurred there, some 479,000, which is second only to the U.S.\nWith players complaining about the location choice, multinational companies began dropping their sponsorship of the games, potentially undermining the games and putting fuboTV's opportunity in jeopardy.\nA case of cold feet\nAmBev (NYSE:ABEV), the Brazilian unit of Anheuser-Busch InBev (NYSE:BUD)and sponsor of the Brazilian national team, announced \"its brands will not be present at the Copa America,\" as did Mastercard (NYSE:MA), which said it would not \"activate\" its sponsorship of the games, something it has done since 1992.\nThat was followed by global spirits distributor Diageo (NYSE:DEO), which said it was withdrawing sponsorship of Copa America \"given the current Brazilian health situation and out of respect for this moment of the COVID-19 pandemic.\"\nParties have gone to court to try to block Brazil from hosting the games, but the country's Supreme Court rejected the injunction bids and said the games could proceed, though they ordered various health and safety measures be implemented.\nThere also don't seem to be any boycotts of the games yet. While the Brazilian national team had called out \"humanitarian\" concerns over locating the games in their home country, it said it would still play.\nAn exclusive opportunity\nThis is why the qualifying games are so critical for fuboTV. To contain the possible spread of COVID-19, Brazilian officials are holding the games without fans present in the stadium, and the teams will undergo testing every 48 hours. Players will also have their movements restricted as they travel between the four host cities.\nThat means fans will need to find alternative means of watching the games, and with the sporting event's huge global popularity, fuboTV has a unique opportunity to see a massive influx of new subscribers to its streaming service.\nSelect English-language games will be available to subscribers who have the fubo Sports Network, but they will only be available on fuboTV and not through the network's usual off-platform distribution partners, such as ViacomCBS' Pluto TV.\nThe Copa America games will be free to current fuboTV subscribers, while new subscribers need to sign up for one of fubo's plans and then add the CONMEBOL & More package for an additional $7 per month. That package includes eight other premium sports channels featuring soccer, baseball, football, basketball, and more.\nIt's still game on\nfuboTV looks like it will avoid a collapse of the Copa America games, though other CONMEBOL games are going off without a hitch so far. As long as other major sponsors stay put, the teams don't boycott, and there are no COVID-19 outbreaks among players, it should be a success.\nThe situation, though, shows just how fragile the sporting world still is as it emerges from the pandemic and tries returning to a sense of normalcy. fuboTV, though, still has enormous growth prospects before it.","news_type":1,"symbols_score_info":{"FUBO":0.9}},"isVote":1,"tweetType":1,"viewCount":610,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":898542626,"gmtCreate":1628514220865,"gmtModify":1633746555899,"author":{"id":"3564622621302285","authorId":"3564622621302285","name":"bluzon","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3564622621302285","idStr":"3564622621302285"},"themes":[],"htmlText":"[财迷]&nbsp;[财迷]&nbsp;[财迷]&nbsp;","listText":"[财迷]&nbsp;[财迷]&nbsp;[财迷]&nbsp;","text":"[财迷] [财迷] [财迷]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/898542626","repostId":"2158446563","repostType":4,"isVote":1,"tweetType":1,"viewCount":2638,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":154786939,"gmtCreate":1625545792021,"gmtModify":1633939773859,"author":{"id":"3564622621302285","authorId":"3564622621302285","name":"bluzon","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3564622621302285","idStr":"3564622621302285"},"themes":[],"htmlText":"Yeah.........","listText":"Yeah.........","text":"Yeah.........","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/154786939","repostId":"1116255026","repostType":4,"isVote":1,"tweetType":1,"viewCount":2994,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":151702121,"gmtCreate":1625105250863,"gmtModify":1633944744039,"author":{"id":"3564622621302285","authorId":"3564622621302285","name":"bluzon","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3564622621302285","idStr":"3564622621302285"},"themes":[],"htmlText":"[得意]&nbsp;[得意]&nbsp;[得意]&nbsp;[得意]&nbsp;[得意]&nbsp;[鬼脸]&nbsp;","listText":"[得意]&nbsp;[得意]&nbsp;[得意]&nbsp;[得意]&nbsp;[得意]&nbsp;[鬼脸]&nbsp;","text":"[得意] [得意] [得意] [得意] [得意] [鬼脸]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/151702121","repostId":"1178516480","repostType":4,"repost":{"id":"1178516480","kind":"news","pubTimestamp":1625094708,"share":"https://www.laohu8.com/m/news/1178516480?lang=zh_CN&edition=full","pubTime":"2021-07-01 07:11","market":"us","language":"en","title":"S&P 500 notches fifth straight record closing high, fifth straight quarterly gain<blockquote>标普500连续第五次创下收盘新高，连续第五个季度上涨</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1178516480","media":"Reuters","summary":"NEW YORK (Reuters) - The S&P 500 nabbed its fifth straight record closing high on Wednesday as inves","content":"<p>NEW YORK (Reuters) - The S&amp;P 500 nabbed its fifth straight record closing high on Wednesday as investors ended the month and the quarter by largely shrugging off positive economic data and looking toward Friday’s highly anticipated employment report.</p><p><blockquote>纽约（路透社）-标普500周三连续第五次创下收盘新高，投资者在本月和本季度结束时基本上摆脱了积极的经济数据，并期待周五备受期待的就业报告。</blockquote></p><p> In the last session of 2021’s first half, the indexes were languid and range-bound, with the blue-chip Dow posting gains, while the Nasdaq edged lower.</p><p><blockquote>在2021年上半年的最后一个交易日，股指低迷且区间震荡，蓝筹股道指上涨，而纳斯达克则小幅走低。</blockquote></p><p> All three indexes posted their fifth consecutive quarterly gains, with the S&amp;P rising 8.2%, the Nasdaq advancing 9.5% and the Dow rising 4.6%. The S&amp;P 500 registered its second-best first-half performance since 1998, rising 14.5%.</p><p><blockquote>三大指数均连续第五个季度上涨，标准普尔指数上涨8.2%，纳斯达克指数上涨9.5%，道指上涨4.6%。标普500上半年表现为1998年以来第二好，上涨14.5%。</blockquote></p><p> “It’s been a good quarter,” said Robert Pavlik, senior portfolio manager at Dakota Wealth in Fairfield, Connecticut. “As of last night’s close, the S&amp;P has gained more than 14% year-to-date, topping the Dow and the Nasdaq. That indicates that the stock market is having a broad rally.”</p><p><blockquote>“这是一个不错的季度，”康涅狄格州费尔菲尔德Dakota Wealth的高级投资组合经理罗伯特·帕夫利克(Robert Pavlik)表示。“截至昨晚收盘，标普今年迄今已上涨超过14%，超过道指和纳斯达克。这表明股市正在出现广泛反弹。”</blockquote></p><p> For the month, the bellwether S&amp;P 500 notched its fifth consecutive advance, while the Dow snapped its four-month winning streak to end slightly lower. The Nasdaq also gained ground in June.</p><p><blockquote>本月，领头羊标普500连续第五次上涨，而道琼斯指数结束了四个月的连涨，小幅收低。纳斯达克在6月份也取得了进展。</blockquote></p><p> This month, investor appetite shifted away from economically sensitive cyclicals in favor of growth stocks.</p><p><blockquote>本月，投资者的兴趣从对经济敏感的周期性股票转向成长型股票。</blockquote></p><p> “Leading sectors year-to-date are what you’d expect,” Pavlik added. “Energy, financials and industrials, and that speaks to an economic environment that’s in the early stages of a cycle.”</p><p><blockquote>“今年迄今为止的领先行业正如你所预期的那样，”帕夫利克补充道。“能源、金融和工业，这表明经济环境正处于周期的早期阶段。”</blockquote></p><p> “(Investors) started the switch back to growth (stocks) after people started to buy in to (Fed Chair Jerome) Powell’s comments that focus on transitory inflation,” Pavlik added.</p><p><blockquote>帕夫利克补充道：“在人们开始接受（美联储主席杰罗姆）鲍威尔关注暂时性通胀的言论后，（投资者）开始转向增长（股票）。”</blockquote></p><p> “Some of the reopening trades have gotten a bit long in the tooth and that’s leading people back to growth.”</p><p><blockquote>“一些重新开放的交易已经持续了一段时间，这正在引导人们恢复增长。”</blockquote></p><p> (Graphic: Growths stocks outperform value in June, narrow YTD gap, )</p><p><blockquote>（图：6月份成长股跑赢价值股，年初至今差距缩小，）</blockquote></p><p> <img src=\"https://static.tigerbbs.com/5b82b4dfdc765d913811f9d8572e60f6\" tg-width=\"964\" tg-height=\"723\" referrerpolicy=\"no-referrer\">“The overall stock market continues to be on a tear, with very consistent gains for quite some time,” said Tim Ghriskey, chief investment strategist at Inverness Counsel in New York. “Valuations, while certainly high by historical standards, have been at a fairly consistent level, benefiting from the economic recovery.”</p><p><blockquote>纽约Inverness Counsel首席投资策略师蒂姆·格里斯基(Tim Ghriskey)表示：“整体股市继续上涨，在相当长一段时间内持续上涨。”“虽然按照历史标准来看估值肯定很高，但受益于经济复苏，估值一直处于相当稳定的水平。”</blockquote></p><p> The private sector added 692,000 jobs in June, breezing past expectations, according to payroll processor ADP. The number is 92,000 higher than the private payroll adds economists predict from the Labor Department’s more comprehensive employment report due on Friday.</p><p><blockquote>根据薪资处理机构ADP的数据，私营部门6月份增加了692,000个就业岗位，轻松超出预期。这一数字比经济学家在劳工部周五发布的更全面的就业报告中预测的私人就业人数高出92,000人。</blockquote></p><p> The Dow Jones Industrial Average rose 210.22 points, or 0.61%, to 34,502.51, the S&amp;P 500 gained 5.7 points, or 0.13%, to 4,297.5 and the Nasdaq Composite dropped 24.38 points, or 0.17%, to 14,503.95.</p><p><blockquote>道琼斯工业平均指数上涨210.22点，涨幅0.61%，至34,502.51点；标普500上涨5.7点，涨幅0.13%，至4,297.5点；纳斯达克综合指数下跌24.38点，涨幅0.17%，至14,503.95点。</blockquote></p><p> Among the 11 major sectors in the S&amp;P, six ended the session higher, with energy enjoying the biggest percentage gain. Real estate was the day’s biggest loser.</p><p><blockquote>在标准普尔11个主要板块中，有6个板块收高，其中能源板块涨幅最大。房地产是当天最大的输家。</blockquote></p><p> Boeing Co gained 1.6% after Germany’s defense ministry announced it would buy five of the planemaker’s P-8A maritime control aircraft, coming on the heels of United Airlines unveiling its largest-ever order for new planes.</p><p><blockquote>德国国防部宣布将购买该飞机制造商的五架P-8A海上控制飞机，波音公司股价上涨1.6%，此前联合航空公布了有史以来最大的新飞机订单。</blockquote></p><p> Walmart jumped 2.7% after announcing on Tuesday that it would start selling a prescription-only insulin analog.</p><p><blockquote>沃尔玛周二宣布将开始销售仅限处方的胰岛素类似物，股价上涨2.7%。</blockquote></p><p> Micron Technology advanced 2.5% ahead of its quarterly earnings release, but was relatively unchanged in after-hours trading following the chipmaker’s quarterly results.</p><p><blockquote>美光科技在季度财报发布前上涨2.5%，但在芯片制造商公布季度业绩后，盘后交易中相对没有变化。</blockquote></p><p> Advancing issues outnumbered declining ones on the NYSE by a 1.35-to-1 ratio; on Nasdaq, a 1.19-to-1 ratio favored decliners.</p><p><blockquote>纽约证券交易所上涨股与下跌股的比例为1.35比1；在纳斯达克，1.19比1的比率有利于下跌股。</blockquote></p><p> The S&amp;P 500 posted 20 new 52-week highs and no new lows; the Nasdaq Composite recorded 70 new highs and 36 new lows.</p><p><blockquote>标普500创下20个52周新高，无新低；纳斯达克综合指数录得70个新高和36个新低。</blockquote></p><p> Volume on U.S. exchanges was 10.85 billion shares, compared with the 11.05 billion average over the last 20 trading days.</p><p><blockquote>美国交易所成交量为108.5亿股，而过去20个交易日的平均成交量为110.5亿股。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>S&P 500 notches fifth straight record closing high, fifth straight quarterly gain<blockquote>标普500连续第五次创下收盘新高，连续第五个季度上涨</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nS&P 500 notches fifth straight record closing high, fifth straight quarterly gain<blockquote>标普500连续第五次创下收盘新高，连续第五个季度上涨</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Reuters</strong><span class=\"h-time small\">2021-07-01 07:11</span>\n</p>\n</h4>\n</header>\n<article>\n<p>NEW YORK (Reuters) - The S&amp;P 500 nabbed its fifth straight record closing high on Wednesday as investors ended the month and the quarter by largely shrugging off positive economic data and looking toward Friday’s highly anticipated employment report.</p><p><blockquote>纽约（路透社）-标普500周三连续第五次创下收盘新高，投资者在本月和本季度结束时基本上摆脱了积极的经济数据，并期待周五备受期待的就业报告。</blockquote></p><p> In the last session of 2021’s first half, the indexes were languid and range-bound, with the blue-chip Dow posting gains, while the Nasdaq edged lower.</p><p><blockquote>在2021年上半年的最后一个交易日，股指低迷且区间震荡，蓝筹股道指上涨，而纳斯达克则小幅走低。</blockquote></p><p> All three indexes posted their fifth consecutive quarterly gains, with the S&amp;P rising 8.2%, the Nasdaq advancing 9.5% and the Dow rising 4.6%. The S&amp;P 500 registered its second-best first-half performance since 1998, rising 14.5%.</p><p><blockquote>三大指数均连续第五个季度上涨，标准普尔指数上涨8.2%，纳斯达克指数上涨9.5%，道指上涨4.6%。标普500上半年表现为1998年以来第二好，上涨14.5%。</blockquote></p><p> “It’s been a good quarter,” said Robert Pavlik, senior portfolio manager at Dakota Wealth in Fairfield, Connecticut. “As of last night’s close, the S&amp;P has gained more than 14% year-to-date, topping the Dow and the Nasdaq. That indicates that the stock market is having a broad rally.”</p><p><blockquote>“这是一个不错的季度，”康涅狄格州费尔菲尔德Dakota Wealth的高级投资组合经理罗伯特·帕夫利克(Robert Pavlik)表示。“截至昨晚收盘，标普今年迄今已上涨超过14%，超过道指和纳斯达克。这表明股市正在出现广泛反弹。”</blockquote></p><p> For the month, the bellwether S&amp;P 500 notched its fifth consecutive advance, while the Dow snapped its four-month winning streak to end slightly lower. The Nasdaq also gained ground in June.</p><p><blockquote>本月，领头羊标普500连续第五次上涨，而道琼斯指数结束了四个月的连涨，小幅收低。纳斯达克在6月份也取得了进展。</blockquote></p><p> This month, investor appetite shifted away from economically sensitive cyclicals in favor of growth stocks.</p><p><blockquote>本月，投资者的兴趣从对经济敏感的周期性股票转向成长型股票。</blockquote></p><p> “Leading sectors year-to-date are what you’d expect,” Pavlik added. “Energy, financials and industrials, and that speaks to an economic environment that’s in the early stages of a cycle.”</p><p><blockquote>“今年迄今为止的领先行业正如你所预期的那样，”帕夫利克补充道。“能源、金融和工业，这表明经济环境正处于周期的早期阶段。”</blockquote></p><p> “(Investors) started the switch back to growth (stocks) after people started to buy in to (Fed Chair Jerome) Powell’s comments that focus on transitory inflation,” Pavlik added.</p><p><blockquote>帕夫利克补充道：“在人们开始接受（美联储主席杰罗姆）鲍威尔关注暂时性通胀的言论后，（投资者）开始转向增长（股票）。”</blockquote></p><p> “Some of the reopening trades have gotten a bit long in the tooth and that’s leading people back to growth.”</p><p><blockquote>“一些重新开放的交易已经持续了一段时间，这正在引导人们恢复增长。”</blockquote></p><p> (Graphic: Growths stocks outperform value in June, narrow YTD gap, )</p><p><blockquote>（图：6月份成长股跑赢价值股，年初至今差距缩小，）</blockquote></p><p> <img src=\"https://static.tigerbbs.com/5b82b4dfdc765d913811f9d8572e60f6\" tg-width=\"964\" tg-height=\"723\" referrerpolicy=\"no-referrer\">“The overall stock market continues to be on a tear, with very consistent gains for quite some time,” said Tim Ghriskey, chief investment strategist at Inverness Counsel in New York. “Valuations, while certainly high by historical standards, have been at a fairly consistent level, benefiting from the economic recovery.”</p><p><blockquote>纽约Inverness Counsel首席投资策略师蒂姆·格里斯基(Tim Ghriskey)表示：“整体股市继续上涨，在相当长一段时间内持续上涨。”“虽然按照历史标准来看估值肯定很高，但受益于经济复苏，估值一直处于相当稳定的水平。”</blockquote></p><p> The private sector added 692,000 jobs in June, breezing past expectations, according to payroll processor ADP. The number is 92,000 higher than the private payroll adds economists predict from the Labor Department’s more comprehensive employment report due on Friday.</p><p><blockquote>根据薪资处理机构ADP的数据，私营部门6月份增加了692,000个就业岗位，轻松超出预期。这一数字比经济学家在劳工部周五发布的更全面的就业报告中预测的私人就业人数高出92,000人。</blockquote></p><p> The Dow Jones Industrial Average rose 210.22 points, or 0.61%, to 34,502.51, the S&amp;P 500 gained 5.7 points, or 0.13%, to 4,297.5 and the Nasdaq Composite dropped 24.38 points, or 0.17%, to 14,503.95.</p><p><blockquote>道琼斯工业平均指数上涨210.22点，涨幅0.61%，至34,502.51点；标普500上涨5.7点，涨幅0.13%，至4,297.5点；纳斯达克综合指数下跌24.38点，涨幅0.17%，至14,503.95点。</blockquote></p><p> Among the 11 major sectors in the S&amp;P, six ended the session higher, with energy enjoying the biggest percentage gain. Real estate was the day’s biggest loser.</p><p><blockquote>在标准普尔11个主要板块中，有6个板块收高，其中能源板块涨幅最大。房地产是当天最大的输家。</blockquote></p><p> Boeing Co gained 1.6% after Germany’s defense ministry announced it would buy five of the planemaker’s P-8A maritime control aircraft, coming on the heels of United Airlines unveiling its largest-ever order for new planes.</p><p><blockquote>德国国防部宣布将购买该飞机制造商的五架P-8A海上控制飞机，波音公司股价上涨1.6%，此前联合航空公布了有史以来最大的新飞机订单。</blockquote></p><p> Walmart jumped 2.7% after announcing on Tuesday that it would start selling a prescription-only insulin analog.</p><p><blockquote>沃尔玛周二宣布将开始销售仅限处方的胰岛素类似物，股价上涨2.7%。</blockquote></p><p> Micron Technology advanced 2.5% ahead of its quarterly earnings release, but was relatively unchanged in after-hours trading following the chipmaker’s quarterly results.</p><p><blockquote>美光科技在季度财报发布前上涨2.5%，但在芯片制造商公布季度业绩后，盘后交易中相对没有变化。</blockquote></p><p> Advancing issues outnumbered declining ones on the NYSE by a 1.35-to-1 ratio; on Nasdaq, a 1.19-to-1 ratio favored decliners.</p><p><blockquote>纽约证券交易所上涨股与下跌股的比例为1.35比1；在纳斯达克，1.19比1的比率有利于下跌股。</blockquote></p><p> The S&amp;P 500 posted 20 new 52-week highs and no new lows; the Nasdaq Composite recorded 70 new highs and 36 new lows.</p><p><blockquote>标普500创下20个52周新高，无新低；纳斯达克综合指数录得70个新高和36个新低。</blockquote></p><p> Volume on U.S. exchanges was 10.85 billion shares, compared with the 11.05 billion average over the last 20 trading days.</p><p><blockquote>美国交易所成交量为108.5亿股，而过去20个交易日的平均成交量为110.5亿股。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.reuters.com/article/us-usa-stocks/sp-500-notches-fifth-straight-record-closing-high-fifth-straight-quarterly-gain-idUSKCN2E619R\">Reuters</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯",".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite"},"source_url":"https://www.reuters.com/article/us-usa-stocks/sp-500-notches-fifth-straight-record-closing-high-fifth-straight-quarterly-gain-idUSKCN2E619R","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1178516480","content_text":"NEW YORK (Reuters) - The S&P 500 nabbed its fifth straight record closing high on Wednesday as investors ended the month and the quarter by largely shrugging off positive economic data and looking toward Friday’s highly anticipated employment report.\nIn the last session of 2021’s first half, the indexes were languid and range-bound, with the blue-chip Dow posting gains, while the Nasdaq edged lower.\nAll three indexes posted their fifth consecutive quarterly gains, with the S&P rising 8.2%, the Nasdaq advancing 9.5% and the Dow rising 4.6%. The S&P 500 registered its second-best first-half performance since 1998, rising 14.5%.\n“It’s been a good quarter,” said Robert Pavlik, senior portfolio manager at Dakota Wealth in Fairfield, Connecticut. “As of last night’s close, the S&P has gained more than 14% year-to-date, topping the Dow and the Nasdaq. That indicates that the stock market is having a broad rally.”\nFor the month, the bellwether S&P 500 notched its fifth consecutive advance, while the Dow snapped its four-month winning streak to end slightly lower. The Nasdaq also gained ground in June.\nThis month, investor appetite shifted away from economically sensitive cyclicals in favor of growth stocks.\n“Leading sectors year-to-date are what you’d expect,” Pavlik added. “Energy, financials and industrials, and that speaks to an economic environment that’s in the early stages of a cycle.”\n“(Investors) started the switch back to growth (stocks) after people started to buy in to (Fed Chair Jerome) Powell’s comments that focus on transitory inflation,” Pavlik added.\n“Some of the reopening trades have gotten a bit long in the tooth and that’s leading people back to growth.”\n(Graphic: Growths stocks outperform value in June, narrow YTD gap, )\n“The overall stock market continues to be on a tear, with very consistent gains for quite some time,” said Tim Ghriskey, chief investment strategist at Inverness Counsel in New York. “Valuations, while certainly high by historical standards, have been at a fairly consistent level, benefiting from the economic recovery.”\nThe private sector added 692,000 jobs in June, breezing past expectations, according to payroll processor ADP. The number is 92,000 higher than the private payroll adds economists predict from the Labor Department’s more comprehensive employment report due on Friday.\nThe Dow Jones Industrial Average rose 210.22 points, or 0.61%, to 34,502.51, the S&P 500 gained 5.7 points, or 0.13%, to 4,297.5 and the Nasdaq Composite dropped 24.38 points, or 0.17%, to 14,503.95.\nAmong the 11 major sectors in the S&P, six ended the session higher, with energy enjoying the biggest percentage gain. Real estate was the day’s biggest loser.\nBoeing Co gained 1.6% after Germany’s defense ministry announced it would buy five of the planemaker’s P-8A maritime control aircraft, coming on the heels of United Airlines unveiling its largest-ever order for new planes.\nWalmart jumped 2.7% after announcing on Tuesday that it would start selling a prescription-only insulin analog.\nMicron Technology advanced 2.5% ahead of its quarterly earnings release, but was relatively unchanged in after-hours trading following the chipmaker’s quarterly results.\nAdvancing issues outnumbered declining ones on the NYSE by a 1.35-to-1 ratio; on Nasdaq, a 1.19-to-1 ratio favored decliners.\nThe S&P 500 posted 20 new 52-week highs and no new lows; the Nasdaq Composite recorded 70 new highs and 36 new lows.\nVolume on U.S. exchanges was 10.85 billion shares, compared with the 11.05 billion average over the last 20 trading days.","news_type":1,"symbols_score_info":{".SPX":0.9,".IXIC":0.9,".DJI":0.9}},"isVote":1,"tweetType":1,"viewCount":2321,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":127110229,"gmtCreate":1624839215561,"gmtModify":1633948237177,"author":{"id":"3564622621302285","authorId":"3564622621302285","name":"bluzon","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3564622621302285","idStr":"3564622621302285"},"themes":[],"htmlText":"Yes........","listText":"Yes........","text":"Yes........","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/127110229","repostId":"2146007118","repostType":4,"isVote":1,"tweetType":1,"viewCount":1864,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":154039874,"gmtCreate":1625458967398,"gmtModify":1633940476216,"author":{"id":"3564622621302285","authorId":"3564622621302285","name":"bluzon","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3564622621302285","idStr":"3564622621302285"},"themes":[],"htmlText":"[得意]&nbsp;[得意]&nbsp;[得意]&nbsp;[得意]&nbsp;[得意]&nbsp;[得意]&nbsp;","listText":"[得意]&nbsp;[得意]&nbsp;[得意]&nbsp;[得意]&nbsp;[得意]&nbsp;[得意]&nbsp;","text":"[得意] [得意] [得意] [得意] [得意] [得意]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/154039874","repostId":"1169840279","repostType":4,"isVote":1,"tweetType":1,"viewCount":2190,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":127135839,"gmtCreate":1624839126321,"gmtModify":1633948239928,"author":{"id":"3564622621302285","authorId":"3564622621302285","name":"bluzon","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3564622621302285","idStr":"3564622621302285"},"themes":[],"htmlText":"👍👍👍👍👍👍","listText":"👍👍👍👍👍👍","text":"👍👍👍👍👍👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/127135839","repostId":"1136989303","repostType":4,"isVote":1,"tweetType":1,"viewCount":612,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":169188716,"gmtCreate":1623821697835,"gmtModify":1634027550501,"author":{"id":"3564622621302285","authorId":"3564622621302285","name":"bluzon","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3564622621302285","idStr":"3564622621302285"},"themes":[],"htmlText":"Gd","listText":"Gd","text":"Gd","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/169188716","repostId":"1128132038","repostType":4,"isVote":1,"tweetType":1,"viewCount":922,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":154030209,"gmtCreate":1625458915501,"gmtModify":1633940476927,"author":{"id":"3564622621302285","authorId":"3564622621302285","name":"bluzon","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3564622621302285","idStr":"3564622621302285"},"themes":[],"htmlText":"[得意]&nbsp;[得意]&nbsp;[得意]&nbsp;[得意]&nbsp;[鬼脸]&nbsp;[鬼脸]&nbsp;[鬼脸]&nbsp;","listText":"[得意]&nbsp;[得意]&nbsp;[得意]&nbsp;[得意]&nbsp;[鬼脸]&nbsp;[鬼脸]&nbsp;[鬼脸]&nbsp;","text":"[得意] [得意] [得意] [得意] [鬼脸] [鬼脸] [鬼脸]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/154030209","repostId":"1169840279","repostType":4,"isVote":1,"tweetType":1,"viewCount":2886,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}